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ABSTRACT 
The mammalian lignan, enterolactone (EL), is a gut microbe metabolite of plant lignan 
secoisolariciresinol diglucoside (SDG), which is most abundant in flaxseed. Numerous 
epidemiological, experimental and clinical studies suggest the protective effects of EL against 
various chronic diseases such as cancer, cardiovascular disease, and inflammation. However, 
EL’s oral bioavailability is low and highly variable due to extensive first-pass metabolism, 
especially glucuronidation, which results in the large amount of glucuronide metabolites but 
low levels of free EL in human plasma. Hepatocytes and enterocytes express 
UDP-glucuronosyltransferases (UGT), the enzymes responsible for the conjugation of 
glucuronic acid to EL. To better understand the contribution of liver and intestine to the 
first-pass glucuronidation, I conducted an in vitro enzyme kinetic analysis of EL 
glucuronidation using hepatic and intestinal microsomal fractions from both human and rat. 
An intrinsic clearance (CLint) value was calculated using the substrate depletion approach. In 
addition to monitoring substrate depletion, high-pressure liquid chromatography (HPLC) 
analysis allowed detection of EL glucuronides, which were further substantiated by LC-MS. 
EL monoglucuronide was identified in rat and human intestinal and liver microsomes. 
Enzyme kinetic studies indicated the extent of hepatic microsomal glucuronidation exceeded 
intestinal glucuronidation in both human and rat, while the human liver CLint value was 
slightly higher than that of rat liver. The CLint value generated in human intestinal microsomes 
was only one third of the value of human liver, whereas, the CLint of rat jejunum or colon was 
one-twentieth of rat liver, suggesting the human intestine makes a greater contribution to EL 
glucuronidation than rat intestine. These results suggest that both liver and intestine contribute 
to EL glucuronidation and the human intestine may exert a greater influence on the first-pass 
glucuronidation of EL than rat intestine, thereby significantly decreasing EL’s oral 
bioavailability. The rat might underestimate the extent of intestinal metabolism of EL relative 
to human.       
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1. INTRODUCTION 
Flaxseed is the richest source of dietary intake of the plant lignan secoisolariciresinol 
diglucoside (SDG). A growing body of evidence suggests that SDG and its metabolites, in 
particular enterolactone (EL), may exert protective effects against cancer and cardiovascular 
disease through diverse mechanisms. Epidemiological studies suggest that the lower risk of 
aforementioned chronic diseases is greatly attributed to the high circulating concentrations of 
EL. However, the systemic concentration of EL is highly variable. The low and varying 
bioavailability of EL might be greatly attributed to extensive first-pass metabolism, which is 
responsible for the low bioavailability of many xenobiotics. In human plasma and urine, the 
principal conjugates of EL are mainly glucuronides, suggesting a significant first-pass effect 
by glucuronidation occurring both in hepatocytes and enterocytes. Nevertheless, the exact 
contributions from liver and intestine are poorly understood.  
Hence, a fundamental understanding of EL glucuronidation in the liver and intestine is 
essential to provide critical information regarding the oral absorption properties of EL, and 
also possibly to infer the potential for drug-lignan interactions. Therefore, in my project, in 
vitro enzyme kinetic studies using rat and human liver and intestinal microsomes with 
determination of intrinsic clearance (CLint), which directly measures the efficacy of enzymes 
to metabolize substrates, allow the comparison of differences of EL glucuronidation between 
the two first-pass metabolism organs and among two species. 
The literature review on flaxseed lignans contains several sections. The first two sections 
give an overview of the regulations as well as benefits and risks of Natural Health Products 
(NHPs) and the status of flaxseed and lignans as NHPs in Canada. It also provides a general 
framework of the production of EL. The third section demonstrates the health benefits of EL 
according to the evidence from both epidemiological and experimental animal studies, 
although the studies are not completely consistent. The next section discusses the various 
mechanisms responsible for the biological effects of EL. The fifth section essentially deals 
with the pharmacokinetics (absorption, metabolism, distribution and excretion) of plant and 
mammalian lignans with an emphasis on the first-pass glucuronidation of EL. The last two 
sections discuss the low systemic levels of EL and the factors possibly accounting for the low 
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bioavailability. The model system is also discussed to explain the significance of including 
both human and rat models into the study.	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2. LITERATURE REVIEW 
2.1. Natural Health Products 
2.1.1. Introduction of Natural Health Products 
In Canada, Natural Health Products (NHPs) are regulated under the Natural Health 
Products Regulations (NHPR), which is different from the regulations for drugs and food. The 
Natural Health Products Directorate (NHPD) in Canada defines NHPs as naturally occurring 
substances which include vitamins and minerals, herbal remedies, homeopathic medicines, 
traditional medicines like traditional Chinese and East Indian medicines, probiotics and other 
products like amino acids and essential fatty acids1. NHPs are widely used around the world, 
with increasing use in Western countries, to ensure health and wellness and/or for their 
putative medical benefits. A recent survey conducted in 2010 showed that 73% of Canadians 
were using NHPs with greater prevalence in older than younger populations2.  
  
2.1.1.1. Regulation of Natural Health Products 
Each NHP must receive market authorization by obtaining a product license based on 
evidence that the product is safe under the recommended conditions of use without a 
prescription, effective for the proposed claims, and of high quality3. NHPD requires evidence, 
which might vary depending on the product and type of health claim, to support the safety and 
efficacy of the NHP according to its recommended conditions of use prior to approval for sale 
in Canada. That evidence must come from human use; animal or in vitro experimental 
evidence may be considered as additional supporting information but cannot be the basis for 
approval4. For health support claims implying treatment, cure, prevention, and risk reduction 
claims related to a major or serious condition, for example a health claim of a 
chemopreventive NHP for cancer prevention, the NHPD requires at least two Phase III trials 
(randomized, controlled, well-designed) and two prospective observational studies5. Other 
information packages that reflect the totality of evidence, including systematic literature 
review, various epidemiological studies, background information and safety data with respect 
to in vitro experiments and animal studies are demanded in support of a requested claim5.  
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Once a product has been assessed the ingredients and claims to ensure safety, efficacy 
and a product of high quality, an eight-digit Natural Product Number (NPN) or Homeopathic 
Medicine Number (DIN-HM) will be granted, indicating that the product is reviewed and 
approved by Health Canada6. Consumers can identify and/or search for licensed products for 
sale in Canada by looking for the NPN or DIN-HM on the label and/or Health Canada’s 
Licensed Natural Health Products Database. In addition to the product license, each NHP sold 
in Canada requires a site license in order to manufacture, package, label and import for sale, 
which should comply with the guidance of Good Manufacturing Practices (GMPs) specifically 
for NHPs3. Since Health Canada has not yet evaluated all NHPs currently on the market, 
products with exemption numbers (EN) can also be sold in Canada. Except for the pre-market 
assessment, Health Canada also requires product license holders to report any serious adverse 
reactions and any serious unexpected adverse reaction to their products3.  
 
2.1.2. Benefits and Risks of Natural Health Products 
NHPs are prevalently employed with drug therapies by consumers to promote health and 
treat diseases such as cold, inflammation, pain, heart diseases, liver cirrhosis, diabetes and 
central nervous system diseases7. The principal reason for the progressive use of NHPs is 
mainly due to the belief that they are natural and, therefore, must be safe and nontoxic. While 
NHPs are generally safe and have few side effects, they are not free of risk. Life threatening 
adverse reactions associated with NHPs have been discovered and reported with increasing 
incidence. Adverse effects can arise from an inherent toxicity of NHPs, manufacturing 
problems like contamination, incorrect ingredients or dosage levels, adulteration with 
pharmacologically active synthetic compounds, and interactions with prescription drugs or 
other NHPs which may lead to the loss of therapeutic efficacy, toxicity or even mortality8.  
 
2.1.2.1. Natural Health Product-drug interactions 
An important risk of NHP usage is the potential for NHP-drug interactions. Numerous 
studies have documented the interactions of NHPs with Phase I enzymes, particularly the 
Cytochrome P450 (P450) enzymes. For instance, St. John’s wort, used worldwide in the 
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treatment of mild to moderate depression, induces CYP3A4, CYP2E1 as well as CYP2C19 
and causes interactions with cyclosporine or antiretrovirals that are substrates of 
aforementioned P450 enzymes9. Kava is another commonly used NHP in Western countries as 
a result of its anxiolytic and sedative properties10. Recently, studies suggest that several 
kavalactones, the assumed active ingredients of kava extracts, are potent inhibitors of several 
enzymes of the P450 system (CYP1A2, 2C9, 2C19, 2D6, 3A4 and 4A9/11), which implies 
kava has a great potential to cause interactions with drugs that are mainly metabolized by the 
foregoing P450 enzymes11.   
Apart from the large numbers of P450 enzyme-mediated NHP-drug interactions, 
emerging evidence has suggested the high potential of Phase II enzymes, principally uridine 
diphosphoglucuronosyl transferases (UGT), to cause NHP-drug interactions. Valerian and 
valerian/hops, popular over-the-counter products for the treatment of sleep disturbances or 
anxiety, have the potential to cause NHP-drug interactions by inhibiting UGT. Significant 
inhibitory effects on the glucuronidation of acetaminophen, oestradiol, and morphines with 
both microsomes and expressed UGT in the presence of valerenic acid were observed, and 
marked reductions were found in UGT1A1 and UGT2B7 activities12. Celastrol, a promising 
anti-tumor agent, exhibited strong inhibitory effects on UGT1A6 and UGT2B7-mediated 
4-methylumbelliferone (4-MU) glucuronidation. The low inhibition kinetic parameters (Ki of 
0.49 and 0.045 µM for UGT1A6 and 2B7, respectively) indicate the possibility of 
celastrol-drug and/or celastrol-containing herb-drug interactions at the therapeutic 
concentration of celastrol for anti-tumor utilization13. Other significant inhibitors of UGT 
enzymes include Epigallocatechin gallate (EGCG) for UGT1A4, milk thistle for both 
UGT1A6 and UGT1A9, saw palmetto (the extracts of its fruits for the treatment of benign 
prostatic hyperplasia) for UGT1A6, and cranberry for UGT1A914.  
A growing concern exists among both consumers and healthcare practitioners due to the 
risk of NHP-drug interactions. Hence, the safety assessment of NHPs is of great importance to 
ensure the safe use of NHPs by consumers. However, the safety assessments of NHPs are not 
simple due to the compositional diversity of NHPs, their product quality as well as lack of 
standardization, and limited information is available on the pharmacological data, underlying 
mechanisms of actions and toxicities15. More work is needed on clinical research and toxicity 
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studies of NHPs to gain a greater understanding of their pharmacokinetics, efficacy and safety 
data. Moreover, it is the consumer’s responsibility to consult and report the side effects to 
their healthcare professionals in order to minimize the risks of toxicity or NHP-drug 
interactions; meanwhile, healthcare professionals should be fully equipped with a thorough 
knowledge of NHPs to counsel their patients16.  
 
2.1.3. Standardization of Natural Health Products 
Since NHPs are exceptionally complicated and contain multiple active phytochemicals 
with distinct pharmacological efficacy and toxicological effects, the pharmacological studies 
and clinical trials involving the identification of the active ingredients, mechanisms of actions, 
NHP-drug interactions and toxicity are very challenging. A principal problem impeding this 
progress is the absence of standardization of NHPs (both on materials and analytical 
methods)17. Recognition of the natural variation and proportions of the many active 
components in the raw material and correct identification of the main components responsible 
for the desired pharmacological effects are very critical in the standardization process, which 
ensures consistent quality and adequate levels of the key components for subsequent clinical 
investigation15,17. Validated methods are vital for the evaluation of pharmacological, 
toxicological and clinical studies of major ingredients17. Therefore, the standardization of 
NHPs is crucial to guarantee the reliability, consistency and reproducibility of the ingredients 
of NHPs for further clinical research.  
  
2.2. Flaxseed Lignans 
2.2.1. Flaxseed 
Flax (Linum usitatissimum) is abundant in fat, protein and dietary fiber. An analysis of 
brown Canadian flax averaged 41% fat, 20% protein, 28% total dietary fiber, 7.7% moisture 
and 3.4% ash18. The composition of flax can vary with genetics, growing environment, seed 
processing and method of analysis19. 
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2.2.1.1. The status of flaxseed and lignans as Natural Health Product in Canada 
Flax products such as oil, whole seeds or milled seeds are one of the most popular 
functional foods used by consumers due to the putative health benefits against degenerative 
diseases such as cardiovascular disease (CVD)20,21 and cancer22,23. Various flaxseed oil 
softgels or capsules and a flax laxative granule have been granted an NPN by Health Canada, 
and are currently available on the market24. Other flax products, for instance, golden flax seed 
and high lignan flax oil, can be purchased but are not approved by Health Canada.  
Flaxseed is a rich source of soluble fiber, α-linolenic acid (ALA) and plant lignan 
secoisolariciresinol diglucoside (SDG), the components of which are proposed to be 
responsible for the biological effects of flaxseed25. However, researchers show a growing 
interest in lignans because of the significant health benefits associated with them. Though a 
large number of epidemiological studies and some in vitro models as well as animal studies 
have shown flaxseed lignans play an important role in the prevention of CVD26-28, diverse 
cancers29-31, oxidative stress and inflammation32,33 and diabetes34,35, flaxseed lignans or the 
purified lignans such as SDG have not been given an NPN, for clinical trials suggesting safety 
and efficacy data are insufficient and pharmacological properties (ADME), toxicities as well 
as drug interactions are not adequately studied.    
 
2.2.2. Dietary Lignans 
According to the International Union of Pure and Applied Chemistry (IUPAC), lignans 
are a large group of natural products derived from cinnamic acid residues, which are 
characterized by the coupling of two C6C3 units as propylbenzene based on nomenclature 
purposes36 (Figure 2.1). Dietary plant lignans exist substantially in foods such as oilseeds, 
cereal grains, legumes, fruits, vegetables and beverages, but ground flaxseed is the richest 
source of the plant lignan secoisolariciresinol diglucoside (SDG), with pinoresinol (PINO) and 
matairesinol (MAT) as minor lignan components37-40. In Canada, secoisolariciresinol (SECO), 
MAT, PINO, and lariciresinol (LARI) content in 121 foods were analyzed and data were 
presented on as is (wet) basis per 100 g and per serving40. Based on the study, the richest 
sources of lignans were flaxseed (379 mg/100 g) and sesame seed (8 mg/100 g), followed by 
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cereals and breads (0.002-7.2 mg/100 g), legumes (0.002-1 mg/100 g), vegetables (0.001-0.6 
mg/100 g), fruits (0.002-0.4 mg/100g), and nonalcoholic and alcoholic beverages (0.9-37.3 
µg/100 g)40. 
 
OH
O
Cinnamic acid                      
12
3
4
5
6
7
8
9
C6C3 unit, propylbenzene  
 
Figure 2.1 The structural makeup of lignans 
 
2.2.3. Production of Enterolignans 
Following administration, dietary lignans undergo transformation by the intestinal 
bacteria before being absorbed into the systemic circulation. As the major plant precursor in 
flaxseed, the SDG complex and then SDG undergo hydrolysis in the gastrointestinal tract 
(GIT) to yield the aglycone plant lignan SECO. SECO then undergoes further metabolism to 
the mammalian lignans, ED and EL, and ED can be oxidized to form EL29,41. As the minor 
lignan components in flaxseed, MAT, PINO and LARI can also be converted to EL in the GIT 
through one and several additional steps, respectively42 (Figure 2.2). A growing body of 
evidence suggests that SDG and its metabolites, in particular EL, may exert protective effects 
against cancers such as prostate, breast and colon cancer22,31,43,44, CVD26,28, inflammation45, 
and oxidative damage through diverse mechanisms including phytoestrogenic46 and 
antioxidant effects47 from both in vitro and in vivo studies. Epidemiological studies also 
suggest that the lower risk of the aforementioned chronic diseases is greatly attributed to high 
circulating concentrations of EL48-51. Hence, as the promising bioactive form of lignan, the 
health benefits, mechanisms of the biological effects as well as the pharmacokinetic properties 
of EL will be discussed below.  
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Figure 2.2 Pathway of the conversion from plant lignans to mammalian lignans ED and EL 
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2.3. EL-Health Benefits 
Compelling data from epidemiological, experimental and clinical studies, suggests that 
lignans, particularly EL, are promising in the prevention of chronic diseases, although the 
results concerning the health benefits of lignans, especially from epidemiological studies, are 
not completely accordant due to the distinct diet habits in populations, varying lignan product 
quality and intake levels used for the research, lack of flaxseed product standardization and 
valid analytical methods and different experimental designs52.  
 
2.3.1. Epidemiological Studies 
Epidemiological studies have suggested the promising anti-cancer effects by large lignan 
consumption and/or high circulating EL levels in the plasma, although some controversial 
studies exist (Table 2.1). Many studies suggest high intake of lignan-rich foods, which contain 
plant precursors such as SECO, MAT, LARI, is significantly associated with reduction of 
breast cancer53-58, while some studies are in opposition to this viewpoint59-61. By measuring 
serum or urinary excretion of enterolignans, especially EL, numerous studies demonstrate high 
plasma concentrations (54 nM)/urinary excretion levels of EL are inversely correlated with 
breast31,48,49, colon50 and prostate cancer51 risk. However, Kilkkinen and coworkers conducted 
a nested case-control study in Finland, and their findings were against the hypothesis that high 
serum EL concentrations were associated with reduced breast cancer risk62. Tonkelaar and 
coworkers also found that higher urinary EL excretion was weakly and nonsignificantly 
associated with an increased breast cancer risk, but this study included a small number of 
cases (88)63. In another population-based case-referent study in Sweden, Hultén showed that 
very low plasma level of EL (2.9 nM) was associated with an increased breast cancer risk in 
all three cohorts, while very high EL plasma levels (58.2 nM) were also associated with an 
increased breast cancer risk in two cohorts64. The conflicting epidemiological results are in 
part due to inadequate databases used in intake estimation, dietary habits, lifestyles and 
lignan-converting bacteria in different populations40. It is notable that a clinical trial by 
Thompson and coworkers showed the potential to reduce tumor growth in patients with breast 
cancer supplemented with flaxseed, the richest dietary source of lignans23.  
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2.3.2. Experimental Animal Studies 
Compared with epidemiological studies, the experimental results from animal models 
regarding health benefits of lignans are more consistent. In an early study, dietary 
supplementation with high intake of flaxseed (5%) or SDG reduced N-methyl-N-nitrosourea 
(MNU)-induced mammary tumor size and number in rats65. Exposure to a diet with 10% 
flaxseed or SDG (equivalent to the amount in 10% flaxseed) during suckling suppressed 
9,10-dimethyl-1, 2-benzanthracene (DMBA)-induced rat mammary tumorigenesis and 
enhanced mammary gland differentiation, suggesting that exposure to lignans at early stage of 
mammary gland development reduces susceptibility to mammary carcinogenesis later in 
life43,66. Supplementation with 2.5 or 5% flaxseed or 2.5 or 5% defatted flaxseed increased 
cecal β-glucuronidase activity and significantly reduced the number of aberrant crypts per 
focus in the distal colon of rats, which implies the colon cancer protective effect of flaxseed 
may be associated with increased β-glucuronidase activity29. In addition, a series of studies by 
Prasad and coworkers have demonstrated both flax lignan complex and SDG have beneficial 
effects in protecting against atherosclerosis26,27,67.  
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Table 2.1  Study of dietary lignans and enterolignans on breast cancer risk  
(Adapted from Buck68) 
R
es
ul
ts
 
Se
ru
m
 E
L 
le
ve
l w
as
 
si
gn
ifi
ca
nt
ly
 in
ve
rs
e 
as
so
ci
at
ed
 w
ith
 B
C
R
 a
m
on
g 
bo
th
 p
re
m
en
op
au
sa
l a
nd
 
po
st
m
en
op
au
sa
l w
om
en
 
B
C
R
 si
gn
ifi
ca
nt
ly
 d
ec
re
as
ed
 
w
ith
 a
 h
ig
h 
in
ta
ke
 o
f t
he
 p
la
nt
 
lig
na
n 
M
A
T 
bu
t n
ot
 S
EC
O
 o
r 
th
e 
su
m
 o
f p
la
nt
 li
gn
an
s. 
H
ow
ev
er
, b
ot
h 
es
tim
at
ed
 
en
te
ro
lig
na
ns
 (E
D
 a
nd
 E
L)
 
w
er
e 
in
ve
rs
el
y 
as
so
ci
at
ed
 w
ith
 
B
C
R
 
Pr
em
en
op
au
sa
l w
om
en
 in
 th
e 
hi
gh
es
t q
ua
rti
le
 o
f d
ie
ta
ry
 
lig
na
n 
in
ta
ke
 h
ad
 re
du
ce
d 
B
C
R
, w
hi
le
 n
o 
as
so
ci
at
io
n 
w
as
 o
bs
er
ve
d 
be
tw
ee
n 
lig
na
n 
in
ta
ke
s a
nd
 p
os
tm
en
op
au
sa
l 
br
ea
st
 c
an
ce
r. 
O
R
, 9
5 
C
I 
an
d 
P 
0.
38
 
(0
.1
8-
0.
77
) 
P=
0.
03
 
M
A
T 
0.
58
 
(0
.3
7-
0.
94
) 
ED
 
0.
61
 
(0
.3
9-
0.
98
) 
EL
 
0.
57
 
(0
.3
5-
0.
92
) 
0.
66
 
(0
.4
4-
0.
98
) 
0.
93
 
(0
.7
1-
1.
22
) 
A
dj
us
te
d 
fa
ct
or
s 
C
om
m
en
ts
 
A
ge
, a
re
a,
 a
ge
 a
t 
m
en
ar
ch
e,
 a
ge
 a
t f
irs
t 
fu
ll-
te
rm
 p
re
gn
an
cy
, 
O
C
, H
R
T,
 fi
rs
t-d
eg
re
e 
fa
m
ily
 h
is
to
ry
 o
f B
C
, 
hi
st
or
y 
of
 B
B
D
, 
ed
uc
at
io
n,
 a
lc
oh
ol
 
in
ta
ke
, s
m
ok
in
g,
 
ph
ys
ic
al
 a
ct
iv
ity
, 
W
H
R
, B
M
I 
Fa
m
ily
 h
is
to
ry
 o
f b
re
as
t 
ca
nc
er
, n
um
be
r o
f 
bi
rth
s, 
du
ra
tio
n 
of
 
br
ea
st
 fe
ed
in
g,
 
to
ta
l-e
ne
rg
y 
in
ta
ke
, 
B
M
I, 
al
co
ho
l, 
ed
uc
at
io
n.
 
FF
Q
 
A
ge
, e
du
ca
tio
n,
 ra
ce
, 
B
M
I, 
ag
e 
at
 m
en
ar
ch
e,
 
pa
rit
y,
 a
ge
 a
t f
irs
t b
irt
h,
 
hi
st
or
y 
of
 B
B
D
, f
am
ily
 
hi
st
or
y 
of
 B
C
, s
m
ok
in
g,
 
to
ta
l-e
ne
rg
y 
in
ta
ke
. 
FF
Q
 
Li
gn
an
 S
tu
di
ed
 
Se
ru
m
 E
L;
 
EL
 c
on
ce
nt
ra
tio
n 
in
 th
e 
lo
w
es
t 
qu
in
til
e 
w
as
 3
.0
 v
s. 
54
.0
 n
M
 in
 th
e 
hi
gh
es
t q
ui
nt
ile
 
Pl
an
t l
ig
na
ns
; 
SE
C
O
 c
on
c.
 in
 th
e 
lo
w
es
t q
ui
nt
ile
 
w
as
 2
75
.2
 v
s. 
14
09
.1
 µ
g/
da
y.
 
M
A
T 
co
nc
. i
n 
th
e 
lo
w
es
t q
ui
nt
ile
 
w
as
 1
9.
5 
vs
. 3
7.
6 
µg
/d
ay
. 
En
te
ro
lig
na
ns
; 
ED
 c
on
c.
 in
 th
e 
lo
w
es
t q
ui
nt
ile
 w
as
 
23
5.
2 
vs
. 5
54
.9
 µ
g/
da
y.
 
EL
 c
on
c.
 in
 th
e 
lo
w
es
t q
ui
nt
ile
 w
as
 
22
6.
9 
vs
. 4
45
.7
 µ
g/
da
y.
 
Pl
an
t l
ig
na
ns
 (s
um
 o
f S
EC
O
 a
nd
 
M
A
T)
 
Li
gn
an
 p
re
cu
rs
or
s c
on
c.
 in
 th
e 
lo
w
es
t q
ui
nt
ile
 w
as
 <
32
9 
vs
. >
67
3 
µg
/d
ay
. 
Li
gn
an
 p
re
cu
rs
or
s c
on
c.
 in
 th
e 
lo
w
es
t q
ui
nt
ile
 w
as
 <
33
7 
vs
. >
71
3 
µg
/d
ay
. 
Po
pu
la
tio
n 
(N
o.
 C
as
es
/T
ot
al
) 
A
ll 
w
om
en
 
(1
94
/4
02
); 
Pr
em
en
op
au
sa
l 
(6
8/
14
3)
; 
Po
st
m
en
op
au
sa
l 
(1
26
/2
59
) 
Pr
em
en
op
au
sa
l 
(2
78
/9
44
) 
A
ll 
(1
12
2/
31
58
); 
Pr
em
en
op
au
sa
l 
(3
15
/9
08
); 
Po
st
m
en
op
au
sa
l 
(8
07
/2
25
0)
 
D
es
ig
n 
an
d 
Lo
ca
tio
n 
Po
pu
la
tio
n 
ba
se
d 
ca
se
-c
on
tro
l 
st
ud
y 
 Fi
nl
an
d 
Po
pu
la
tio
n 
ba
se
d,
 
ca
se
-c
on
tro
l 
 G
er
m
an
y 
Po
pu
la
tio
n 
ba
se
d,
 
ca
se
-c
on
tro
l 
 U
S 
St
ud
y 
31
Pi
et
in
en
 
 20
01
 
53
Li
ns
ei
se
n 
 20
04
 
54
M
cC
an
n 
 20
04
 
 13 
Table 2.1 (Continued) 
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cancer risk; PCR, prostate cancer risk. 
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2.4. EL-Mechanisms for Bioactivities 
The underlying mechanisms responsible for the bioactivities of either naturally occurring 
lignans or their metabolites generally pertain to the antioxidant activity, the influence of 
lignans on hormone mechanisms, the estrogenic and anti-estrogenic effects, and an impact on 
gene expression and/or enzyme activity69. Based on numerous studies, the enterolignans, 
particularly EL, essentially account for these functions.  
 
2.4.1. Antioxidant Activity 
Oxidant by-products reactive oxygen species (ROS) such as superoxide (O2ˉ·), hydrogen 
peroxide (H2O2), and hydroxyl radical (·OH) of normal metabolism often cause oxidative 
damage to DNA, proteins and lipids which give rise to degenerative diseases of aging such as 
cancers, CVD, immune-system decline and brain dysfunctions70. A number of studies provide 
evidence that plant lignans are capable of enhancing antioxidant defense mechanisms33,47,71-73. 
The antioxidant activities of the flaxseed lignan, SDG, and its mammalian lignans, enterodiol 
(ED) and enterolactone (EL) were evaluated in both lipid and aqueous in vitro model 
systems33. All three lignans significantly (p ≤ 0.05) inhibited linoleic acid peroxidation at both 
10 and 100 µM and DNA scissions in a concentration-dependent manner. In addition, SDG 
demonstrated the weakest activity at scavenging ·OH compared to ED and EL at both 10 and 
100 µM33. A study comparing the antioxidant activity of SECO, ED and EL against SDG and 
vitamin E showed that the antioxidant activity was highest with SECO and ED and lowest 
with vitamin E, and SECO, ED, and EL were respectively 3.82, 3.95, and 3.43 more potent 
than SDG, which may suggest the effectiveness of SDG in hypercholesterolemic 
atherosclerosis, diabetes, and endotoxic shock is generally due to its metabolites73.     
   
2.4.2. Estrogenic and Anti-estrogenic Effects 
The steroid hormone estrogen influences the growth, differentiation, and functioning of 
many target tissues including female and male reproductive systems such as mammary gland, 
uterus, vagina, ovary, testes, epididymis and prostate74,75. Given the widespread role for 
estrogen in human physiology, estrogen is involved in the development or progression of 
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many diseases such as cancer (breast, ovarian, colorectal, prostate, endometrial), osteoporosis, 
neurodegenerative diseases, CVD and obesity, in some of which estrogen mediates its effects 
through binding the estrogen receptor (ER)76. ER, existing in 2 main forms ERα and ERβ, has 
distinct tissue expression patterns in both humans and rodents77. ERα and ERβ have high 
sequence homologies in the DNA binding domain (> 90%) and in the ligand binding domain 
(~60%)78. ER contains two transcriptional activation domains: the autonomous transcriptional 
activation domain AF-1, which is located at the N-terminus, and the lignan-dependent 
activation domain AF-2, located at the C-terminus; however, the primary sequence of AF-2 
differs significantly between ERα and ERβ. This gives rise to different agonist/antagonist 
features of various chemicals69.    
Xenobiotics such as environmental or industrial chemicals and phytoestrogens that can 
interfere with the hormonal or endocrine system can mimic estrogen by binding to ER and 
induce (agonize) steroid response to cause estrogenic effects, or inhibit (antagonize) to prevent 
estrogenic activity, resulting in antiestrogenic effects79,80. The estrogenic or antiestrogenic 
effects at the cellular and molecular level are affected by many factors such as concentration 
dependency, receptor status, presence or absence of endogenous estrogens, and the type of 
target organ or cell81. 
Lignans have received considerable attention as a source for phytoestrogens. Based on a 
study examining the mechanism to interfere with ER by which enterolignans exert estrogenic 
and/or antiestrogenic effects, it indicated that enterolignans had distinct properties for 
transactivation of ERα and ERβ. ED, as estradiol (E2), induced ERα transcriptional activation 
through transactivation functions AF-1 and AF-2, while EL was less efficient in inducing 
AF-1 but acted predominantly through AF-282.  
The estrogenic effects of enterolignans were evaluated by some studies. In an early study, 
Sathyamoorphy found that EL at 1 µM was able to produce a weak estrogenic response, while 
ED at 1 µM was inactive. In addition, MCF-7 cell proliferation in the presence of 1 µM EL 
was 92% compared with cells treated with 0.1 nM E2, whereas the addition of ED at the same 
concentration did not show growth stimulation83. In another study, E2 (1 nM) and EL (0.5-2 
µM) separately stimulated the proliferation of MCF-7 cells, but their combination had no 
stimulatory effect compared to control84, which might result from the competition between EL 
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and E2 on binding to the ER.   
An antiestrogenic effect was also observed by some studies. Saarinen proposed that EL 
potently down regulated E2-stimulated angiogenic factors derived both from the stroma and 
the cancer cells46. Higher concentrations above 10 µM of EL inhibited MCF-7 cells 
significantly84. EL was evaluated for its effects on DNA synthesis in MCF-7 cells. Based on 
the analysis, EL was found to have a biphasic effect on DNA synthesis, exhibiting induction at 
10-50 µM (with a peak value of 210% at 10 µM) and inhibition at high concentrations, with an 
IC50 (half maximal inhibitory concentration) of 82.0 µM85.  
According to the above analysis, EL is likely essential for the estrogenic and 
antiestrogenic activities of flaxseed, suggesting the significance of the transformation from 
plant lignans to enterolignans by the intestinal bacteria. However, the serum concentration of 
EL in humans is normally < 10 µM and most often < 1 µM52. Therefore, a stimulatory effect 
on cell growth rather than inhibition is more likely to happen. The agonistic properties of EL 
might apply for conventional hormone replacement therapy in postmenopausal women. 
Nevertheless, the potential cell growth simulation and the ability to induce 
estrogen-responsive genes of EL need to be paid particular attention when used on 
hormone-dependent breast cancer patients69.  
 
2.4.3. Binding to Some Proteins (SHBG and SBP) 
Sex hormone binding globulin (SHBG) and sex steroid binding protein (SBP), 
glycoproteins in human plasma, have high affinity towards endogenous estrogens86. Lignans 
are proposed to potentially increase plasma SHBG and SBP levels, which then bind a large 
proportion of endogenous estrogens, thus decrease the free plasma estrogen and testosterone 
levels available to the cancer cells52,87. One study evaluated the correlation between intake of 
various fibers, lignan excretion and plasma levels of estrogens, free testosterone and SHBG in 
women and demonstrated a significant positive correlation between fiber intake and urinary 
excretion of lignans, and the concentration of plasma SHBG88. In addition, EL excretion 
correlated negatively with plasma percentage free estradiol and testosterone suggesting that 
fiber-rich foods containing lignans might stimulate SHBG and in this way to reduce levels of 
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free hormone in plasma88. In an in vitro study EL stimulated the synthesis of SHBG by HepG2 
liver cancer cells in culture acting synergistically with estradiol, which implied that lignans 
may affect uptake and metabolism of sex hormones by participating in the regulation of 
plasma SHBG levels89. Furthermore, Martin and coworkers studied the interactions of SBP 
and the lignans EL, ED, Nordihydroguaiaretic (NDGA) as well as isoflavonoid 
phytoestrogens (equol, diazein, and genistein). This researcher found that the phytoestrogens 
had different dose-dependent inhibitory effects on steroid binding by SBP, with relative 
efficiencies EL≥NDGA=equol>genistein for displacing E2, but ED and diazein were much 
less active87.  
 
2.4.4. Influence on Enzyme Activity 
The mammalian lignans, especially EL, can inhibit several steroid metabolizing enzymes 
including aromatase, 5α-reductase, 7α-hydroxylase and 17β-hydroxysteroid dehydrogenase 
(17β-HSD)52. Aromatase, also named estrogen synthetase, is a cytochrome P450 enzyme 
responsible for catalyzing the conversion of androgens to estrogens90. EL was a moderate 
inhibitor of aromatase, while ED was a relative weak inhibitor in a human preadipose cell 
culture system91,92. Such activity suggests that the high concentration of lignans in vegetarians, 
via inhibiting aromatase in peripheral and/or cancer cells and lowering estrogen levels, may 
play a protective role against estrogen-dependent cancers92.  
The inhibition of 5α-reductase and 17β-HSD by lignans in human genital skin fibroblast 
monolayers and homogenates, and in benign prostatic hyperplasia tissue homogenates was 
reported93. EL inhibited both 5α-reductase and 17β-HSD in genital skin fibroblasts, and EL 
was the most potent inhibitor of 5α-reductase93. EL inhibited E2 production via inhibition of 
the 17β-HSD type 1 pathway94. Additionally, the reduction in E2 production by EL was 
significantly related to a reduction in MCF-7 cell proliferation94.  
 
2.5. Pharmacokinetics of Plant and Mammalian lignans 
The pharmacokinetic properties of plant as well as mammalian lignans are rather 
complex and not thoroughly characterized. This section will summarize the absorption, 
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metabolism, distribution and excretion of lignans, with emphasis on the conjugative 
glucuronidation of EL. 
 
2.5.1. Absorption 
2.5.1.1. The absorbable form of lignans 
An oligomer composed of five SDG residues interconnected by four 3-hydroxy-3-methyl 
glutaric acid (HMGA) residues is identified as the main lignan of flaxseed95. SDG oligomers 
in the flaxseed extract are often hydrolyzed to break the ester linkages for the release of SDG 
and the glycosidic bonds for the release of SECO96. No studies specifically investigated 
whether SDG or the aglycone SECO is the absorbable form of lignans. Nevertheless, some 
indirect evidence suggests that the aglycone form SECO is primarily absorbed. Caco-2 cells 
derived from human colon adenocarcinoma were used as a model to investigate the 
bidirectional permeation (100 µM SDG, SECO, ED and EL) in our lab (manuscript under 
review). The results showed that the apical-to-basolateral and basolateral-to-apical permeation 
rates for SDG could not be calculated as SDG levels were below 50 ng/mL (0.0728 µM) under 
the level of quantification of our developed HPLC assay. However, permeation of SECO, ED 
and EL occurred in both of the apical-to-basolateral as well as basolateral-to-apical directions. 
In another study, the uptake of EL and ED by human colon epithelial cells was observed as the 
intracellular levels of conjugated EL and ED in HT29 cells rose immediately after starting the 
exposure, suggesting EL and ED are likely to permeate the colon epithelial cells and undergo 
phase II metabolism97.  
Most of the lignan metabolites other than SDG were found in their conjugated forms in 
the portal vein after oral administration of flaxseed in rats98. An investigation showed that 
only in 5% of the 150 diphenolic fractions extracted from the urine of women plant lignans 
including LARI, isolariciresinol, MAT and SECO were identified, but SDG was not found in 
the urine99. When female rats were given a gavage of 3H-SDG (3.7 kBq/g body), ED, EL and 
SECO accounted for 75-80% of urine radioactivity, while SDG was not detected in the 
urine100. The aforementioned data suggest that no measurable SDG levels in plasma and/or 
urine are found after flaxseed or pure SDG supplementation. Additionally, several distinct 
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forms of aglycone were found after anaerobic incubation of SDG with a human fecal 
suspension, which demonstrates intestinal microflora is capable of transforming SDG into 
other aglycone forms101. Therefore, SDG is converted to its aglycone form, SECO, in the 
small intestine, which is subsequently absorbed or undergoes further conversion to the 
enterolignans. 
 
2.5.1.2. Pharmacokinetic parameters of lignans 
A pharmacokinetic study in rats following a single oral bolus dose of pure lignans (SDG, 
SECO, ED and EL was 40, 40, 10 and 5 mg/kg, respectively) and an intravenous bolus dose of 
lignans (SDG, SECO, ED and EL was 20, 20, 5 and 1 mg/kg, respectively) indicated that the 
serum concentration of SDG following oral administration was below the limit of 
quantification (0.0728 µM) at all time points, whereas SDG level following intravenous 
dosing was detectable up to 4 h (manuscript under review). The concentrations of SECO in 
intravenous and oral serum samples were detected up to 8 h and 4 h, respectively. The oral 
pharmacokinetic profile of SECO exhibited a very rapid absorption such that Cmax (the 
maximum drug concentration in the blood) was achieved at 5 min. Quantifiable levels of ED 
were obtained up to 4 h post dose following both oral and intravenous administration. Besides, 
SECO exhibited the highest bioavailability of ~25% in rats while SDG and ED showed poor 
oral bioavailability. Another pharmacokinetic analysis of SECO was performed in rats 
following a bolus intravenous injection (SECO was 20 mg/kg)102. The systemic clearance (Cls) 
for SECO was 7.3 ± 1.1 L/h kg, elimination rate constant (k) was 0.15 ± 0.01h-1 and half life 
(t1/2) was 4.5 ± 0.4 h. Volume of distribution (Vd) for SECO was 47.4 ± 10.9 L/kg and area 
under the curve (AUC0-∞) was 2.79 ± 0.41 h*µg/mL102.   
In twelve healthy men and women enterolignans appeared in plasma 8-10 h after 
ingestion of a single dose of purified SDG (1.31 µM/kg body wt.)103. ED reached its 
maximum plasma concentration 14.8 ± 5.1 h after ingestion of SDG, whereas EL reached its 
maximum 19.7 ± 6.2 h after ingestion. The mean elimination half-life of ED (4.4 ± 1.3 h) was 
shorter than that of EL (12.6 ± 5.6 h). The mean residence time for ED was 20.6 ± 5.9 h and 
that for EL was 35.8 ± 10.6 h103. In another seven volunteers EL plasma levels and urinary 
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excretion were measured after the administration of a single dose of strawberries (500 g) 
equivalent to 11.7 mg of SECO and 0.61 mg of MAT104. EL appeared in plasma 8 h after the 
post meal, and reached the maximum at 24 h. Maximum EL excretion was observed in 25-36 
h urine samples104. 
 
2.5.1.3. Conversion of lignans in human gastrointestinal tract 
In vitro conversion of plant lignans by human fecal flora101,105,106, germ-free rats98 and 
humans taking antimicrobials107 demonstrates intestinal bacteria play a crucial role in the 
production of enterolignans. Intestinal bacteria metabolize plant lignans by a series of 
processes including deglycosylation, ring cleavage, demethylation, dehydroxylation and 
oxidation69,101. Strains of Bacteroides and Clostridium genera deglycosylate SDG to form 
SECO108. It is suggested that the conversion occurs between terminal ileum and caecum in 
pigs109. Similarly, Eeckhaut and his coworkers proposed SDG was only hydrolyzed into 
SECO through microbial action in the ascending colon110, which is supported by an early 
study in eight ileostomy patients having low plasma and urine lignan levels111. Subsequently, 
SECO is partially absorbed into systemic circulation and/or is biotransformed into mammalian 
lignans112,113. SECO undergoes dehydroxylation and demethylation catalyzing by strains of 
Ruminococcus products and Eggerthella lenta to yield ED, which can be further oxidized to 
form EL by Lactonifactor longoviformis108. As the minor lignan components in flaxseed, 
MAT, PINO and LARI can also be converted to EL by the bacterial flora through one and 
several additional steps, respectively42. Figure 2.3 outlines the bioconversion from plant 
lignans to mammalian lignans by the intestinal microflora in the gastrointestinal tract. 
Apparently, diverse bacteria communities are favorable to the transformation of plant lignans 
to mammalian lignans; thus, the variation of intestinal bacterial may result in large 
inter-individual difference on EL levels.  
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Figure 2.3 Diagram of the intestinal microflora mediated conversion of lignans in human 
gastrointestinal tract.  
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2.5.2. Metabolism 
Once mammalian lignans are absorbed, they undergo primarily phase II metabolism prior 
to systemic circulation, with the predominant formation of conjugative metabolites, 
particularly EL glucuronides97,114,115.  
 
2.5.2.1. Oxidative metabolism 
Oxidative metabolism of enterolignans is principally mediated by hepatic P450 enzymes. 
Human and rat hepatic microsomes biotransform EL to oxidative metabolites with an 
additional hydroxyl group either at the aromatic or aliphatic moiety116. A study evaluating the 
metabolic fate of EL and ED by ingesting flaxseed to humans showed that monohydroxylated 
EL and ED metabolites were identified at the para- and ortho-positions on either aromatic ring, 
which indicated the lignan was oxidatively metabolized in vivo117. This is in agreement with 
the results found in rats where several hydroxylated metabolites of EL and ED were found in 
bile and urine after feeding a diet containing 5% flaxseed114 (Figure 2.4 and Figure 2.5). 
Nevertheless, the phase I metabolites of enterolignans represent a minor percent when 
compared with phase II metabolites115,117. 
 
 
 
Figure 2.4 Oxidative metabolites of ED (Adapted from Alister D. Muir118) 
 25 
 
 
 
Figure 2.5 Oxidative metabolites of EL (Adapted from Alister D. Muir118) 
 
2.5.2.2. Conjugative metabolism 
2.5.2.2.1. UDP-glucuronosyltransferases 
The UDP-glucuronosyltransferases (UGT) are a superfamily of endoplasmic reticulum 
membrane-bound enzymes, utilizing UDP-glucuronic acid as a cosubstrate for the formation 
of glucuronides from substrates such as steroids, bile acids, hormones and thousands of 
xenobiotics that include drugs, environmental toxicants and carcinogens, the process of which 
is known as glucuronidation119. Glucuronidation transforms lipophilic substrates into 
hydrophilic glucuronides, more water-soluble compounds that can be subsequently eliminated 
through the bile and urine. Thus, the glucuronidation pathway is primarily regarded as a 
detoxification reaction120. The highest UGT activities frequently occur in the microsomal 
fractions extracted from the liver, kidney and intestine, and various factors such as age, gender, 
hormonal status, genetic factors as well as environmental exposures will exert great influence 
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on the exact composition of UGT in tissues120.  
In humans, four UGT families have been identified including UGT1, UGT2, UGT3, 
UGT8, in which UGT1 and UGT2 mainly use UDP-glucuronic acid to glucuronidate 
endogenous substances and xenobiotics including lignans, flavonoids and isoflavones that are 
not accessible for UGT3 and UGT8 families121. Up to now, UGT1 family includes 9 
functional isoforms in humans, and 7 in rat; UGT2 include 6 members in humans and 7 in 
rat119-121. Since the expression of UGT in the same and/or different organs between humans 
and rats is different, species difference in glucuronidation can be expected.  
  
2.5.2.2.2. Enterolignan glucuronidation  
ED and EL undergo hepatic phase II reactions, primarily glucuronidation, with minor 
contributions to phase II metabolism by sulfotransferases122,123. ED and EL were incubated 
with rabbit liver microsomal UGT and the lignan glucuronides were purified. The 
monoglucuronide conjugates of each lignan were confirmed, which indicated the hepatic 
microsomal UGT system conjugated EL to either phenolic hydroxyls and ED to either 
non-phenolic or phenolic hydroxyl groups124 (Figure 2.6). Dean and coworkers also 
substantiated that EL underwent extensive glucuronidation with rhesus liver microsomes to 
form O-glucuronides at both phenolic hydroxyl groups115 (Figure 2.7). Additionally, 
incubations of EL with human and rhesus hepatocytes resulted in a large percent of glucuronic 
acid conjugates, with minor amounts of the sulfate conjugates and monohydroxylated 
products115.  
In addition to the hepatic glucuronidation, several studies have demonstrated the 
intestinal glucuronidation of enterolignans. Human colon epithelial cells (HT29 and Caco-2) 
can take up, metabolize and excrete the enterolignans EL and ED, and these cell lines produce 
conjugation products, which exist as EL monoglucuronide, EL sulfate and ED glucuronide. 
Moreover, more than 90% of the EL in the medium was present in its conjugated form within 
10 h, however in vivo a significant amount of EL is probably conjugated by the intestinal cells 
before entering the circulation97. The extent of glucuronidation and sulfation of lignans (SDG, 
SECO, ED and EL) in the Caco-2 monolayer was also assessed in our own lab (manuscript 
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under review). Limited conjugation of SDG was observed up to 48 h of incubation with 
Caco-2 cells, but SECO, ED and EL exhibited significant conjugation. Hydrolysis of cell 
lysate and supernatant media with β-glucuronidase/sulfatase enzyme showed less than 3% 
SDG conjugation. SECO and ED presented 95% and 90% conjugation, respectively, while EL 
was completely conjugated within 8 h. This implies that lignans undergo extensive and 
significant first-pass metabolism prior to systemic circulation.  
Subsequently, conjugated lignans are excreted back to the digestive tract via bile, 
reabsorbed from the intestine, and eventually are excreted in the urine as glucuronide 
conjugates, a process known as enterohepatic circulation98 (Figure 2.8). This process enhances 
the exposure of enterolignans to intestine and liver, resulting in further substantial conjugation 
reactions.   
Most of the ED and EL detected in the portal vein of rats were present principally as 
glucuronide conjugates98. In a plasma analysis of enterolignans in 27 pre- and postmenopausal 
women approximately 80% total enterolignans were present as monoglucuronides, with minor 
a percent of diglucuronides and sulfoglucuronides123. The excretion of enterolignans in urine 
and bile was largely as glucuronides, while mono- and disulphates were also found98. In 
human urine, 92% of ED and 98% of EL in the glucuronide fraction were observed, in which 
84.5% monoglucuronide of ED and 94% monoglucuronide of EL occurred in the glucuronide 
fractions125. 
Thus, most of the absorbed dose of lignans predominantly exists as monoglucuronide 
conjugates. These findings raise some important questions regarding the bioactive lignan form, 
i.e. whether the plant lignans or their conjugates, or the mammalian lignans or their conjugates 
mediate the positive health benefits of flaxseed consumption. Traditionally, glucuronidation is 
considered as a reaction that results in the loss of pharmacological activity of xenobiotics and 
rapid excretion. However, several glucuronide conjugates are known to possess biological 
effects. For instance, a widely used opioid analgesic 6-O-glucuronide of morphine contributes 
to the pharmacological activity in addition to the parent compounds120. Given the high 
concentrations of enterolignans glucuronides, the pharmacological activity of these 
glucuronides needs further study.
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Figure 2.6 Conjugative glucuronidation metabolites of ED 
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Figure 2.7 Conjugative glucuronidation metabolites of EL 
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Figure 2.8 The enterohepatic circulation of plant lignans, their colonic and liver metabolites 
(Adapted from Setchell 1982126) 
 
2.5.3. Distribution 
Despite the biological forms of lignans that are beneficial to human health, the efficient 
delivery of drugs from the site of administration to the target organs, tissues or receptors is 
required. However, little is known about the lignan distribution and the concentrations in the 
tissues, which are essential to understand their pharmacological effects and underlying 
mechanisms of pharmacological action. Some general information observed in tissue 
distribution studies is presented below. 
In rats, a dose-related increase in the tissue distribution of ED and EL was observed in rat 
liver, testes, prostate and lung after administration of SDG, where the liver and prostate 
achieved the highest concentrations of ED (1.844 and 1.899 pmol/mg, respectively) of all 
tissues examined at the 60 mg/kg SDG, a significant increase over the levels obtained in the 
controls and 15 mg/kg dose group127. In addition, lung exhibited a significant 2.8-fold increase 
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in EL concentration with the dosage of SDG increase from 15 to 60 mg/kg127. Lignans, but 
only in the form of EL, were also detected in the tissue of colon, liver, breast and brain at a 
much higher level with rye than wheat when high-fiber wheat and high-fiber rye bread 
administered to pigs for 58-67 d112. Tissue accumulation of lignans in human prostate and/or 
breast cyst fluids was observed in several studies, suggesting an anticarcinogenic effect 
towards prostate and breast cancer. In the semen of 6 men, EL existed in both conjugated and 
unconjugated forms at the mean concentration of 183 nM, which was much greater than 73 
nM in the blood128. In the semen of 4 bulls, the mean concentration of total conjugated and 
unconjugated EL was 3200 nM, an order of magnitude higher than that was in the blood (228 
nM)128. In 191 women, the median intracystic level of EL (63 nM) was approximate four 
times higher than the median value of serum EL (17 nM)129. Therefore, the accumulation of 
EL in prostate and/or breast cyst fluids might be, in part, responsible for decreasing the 
prostate and/or breast cancer risk. 
Chronic or prolonged administration of SDG might alter lignan distribution. 3H-SDG 
disposition in female rats with acute or chronic SDG treatment over 48 h (3.7 kBq/g body 
weight 3H-SDG versus 1.5 mg unlabeled SDG/d) was evaluated by the Thompson group. The 
results found that tissue radioactivity was highest (by 0.5 to 176-fold) in the cecum, and levels 
in the liver, kidney and uterus were 0.2- to 7.5-fold higher than in other nongastrointestinal 
tissues130. Also, cecal content, liver and adipose radioactivity were one-to-threefold greater in 
rats with chronic SDG exposure as compared with acute exposure130. In a later study by the 
same research group 3H-SDG administration (3.7 kBq/g body weight) resulted in an increased 
radioactivity in all tissues (liver, kidneys, bladder, spleen, lungs, brain, thymus, heart, muscle, 
adipose, mammary gland, ovaries, vagina, uterus, testis, seminal vesicles, coagulating glands 
and ventral prostate) examined in both male and female rats, and the levels were further 
increased after prolonged SDG exposure, while liver contained the majority of the tissue 
lignans (48-56%) in both sexes after 1 d or 7 d exposure regimens131. After prolonged 
exposure, females had higher lignan concentrations in heart and thymus, demonstrating 
sex-related differences in lignan tissue distribution131. Hence, the foregoing data suggest 
lignans mainly accumulate in the liver, prostate, kidney and intestine. However, it is 
noteworthy that the tissue distribution of lignans was mostly investigated through animal 
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models such as rats; thus, careful attention should be paid when extrapolating the distribution 
pattern from animals to humans.  
Since only the unbound form of a compound can exert an effect, the extent to which 
lignans bind to serum protein is of importance. However, limited information about the 
plasma protein binding data of flaxseed lignans is available in the literature. SDG, SECO, ED 
and EL (each 50 µg/mL) were evaluated for their serum protein binding capacity in rat serum 
by our developed HPLC method (manuscript under review). The results showed that SDG was 
not bound to serum protein, while SECO, ED and EL displayed increasing serum protein 
binding characteristics in an ascending order. This similar trend of the binding affinities of 
SECO, ED and EL was also observed with steroid hormone binding globulins (SHBG) that 
SECO and EL had higher binding affinity than ED132. Besides, SECO and EL displaced 60 ± 
7% and 55 ± 7% of 3H-dihydrotestosterone (DHT) from the binding site, respectively, whereas 
ED exhibited only 16 ± 6%133. 
 
2.5.4. Excretion 
Urinary excretion is one of the primary routes of excretion of lignan metabolites. The 
excretion of enterolignans in urine and bile were mainly as glucuronides, while small amounts 
of mono- and disulphates were also found98. In human urine, 92% of ED and 98% of EL in the 
glucuronide fractions were observed125. A very small percent of plant lignans was also 
excreted in the urine, which might result from an insufficient metabolic capacity of intestinal 
bacteria99. The urinary excretion of EL varied from 1 to 4.2 µM/24 h134,135, and the urinary 
excretion of enterolignans is significantly related to lignan intake. Rickard and coworkers 
conducted a study in rats fed ground flaxseed (2.5, 5 or 10 g/100 g) or SDG (1.1, 2.2 or 4.4 
mM), and found that urinary lignan excretion increased linearly with doses from 0-5% 
flaxseed and 0-2.2 mM SDG/d136. In postmenopausal women consuming 5 or 10 g of ground 
flaxseed/d, urinary excretion of ED was increased by 1,009 and 2867 nM/d, while urinary 
excretion of EL was enhanced by 21,242 and 52,826 nM/d137.  
Fecal excretion is another major route of excretion of lignan metabolites. Fecal excretion 
of the lignans ED, EL and MAT increased significantly with flax consumption, from 80 to 
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2560, 640 to 10300 and 7.33 to 11.9 nM/d138. Excretion in feces of pigs, predominantly in the 
form of EL, represented 46% of the intake when pigs were fed rye diet containing high percent 
of lignans139. This is somewhat higher than that which was found in humans, where 34-35% 
(mean) of the mammalian lignans were excreted through the fecal route139. When rats were 
given a single gavage of 3H-SDG, >80% of the recovered dose was excreted in both feces (> 
50%) and urine (28-32%) after 48 h130. The high fecal excretion of enterolignans may be due 
to the incomplete absorption or enterohepatic circulation. 
 
2.6. Bioavailability of EL 
The proposed health benefits of lignans have promoted its consumption by individuals 
suffering from various chronic diseases. However, systemic levels of EL are highly variable in 
the population. Several factors are crucially responsible for the varying circulating EL 
concentrations, which are discussed below. 
 
2.6.1. Dietary and Lifestyle Determinants 
Dietary and lifestyle determinants are important factors that influence circulating EL 
concentrations. Dietary components such as whole-grain products, vegetables, fiber and coffee 
showed positive associations with plasma EL concentration, while negative associations were 
observed among body mass index (BMI), smoking and frequency of bowel movements with 
plasma EL concentration140-142.  
 
2.6.2. Interindividual Variation of Gut Microflora 
Interindividual variations in bacteria lead to significant differences of lignan metabolism 
in the population, which can be separated into high, moderate and low mammalian lignan 
producers143. In vitro SECO incubation with human fecal samples showed that higher 
proportions of Peptostreptococcus products and related species, as well as bacteria belonging 
to the Atopobium group were typical for moderate to high concentrations of EL-producing 
communities106, while ED production correlated negatively with Clostridium 
coccoides-Eubacterium rectale counts143. Furthermore, since gut bacteria are critical in the 
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formation of EL from plant precursors, factors that affect lignan-converting bacteria will 
potentially influence the absorbable level of EL. As enterolignans precursors usually occur in 
fiber-rich foods, dietary fiber might play a profound role on the number and diversity of 
bacteria that inhabit the large intestine144. The presence of fermentable dietary fiber in 
lignan-rich foods is likely to increase microfloral bacteria level, resulting in an enhanced level 
of EL. Another influential factor on intestinal bacteria is antibiotics. The impact of antibiotics 
on EL concentration has been reported by several studies, which suggested that the 
concentration of EL in blood was reduced by antibiotics among those who had used antibiotics 
during the preceding year107,145. Consequently, interindividual variation in the density and 
diversity of gut microflora may significantly contribute to varying levels of EL. 
 
2.6.3. First-pass Glucuronidation  
Another critical factor causing the variable systemic concentrations of EL is its low and 
varying bioavailability owing to the extensive first-pass glucuronidation. In human plasma and 
urine, the principal conjugates of EL were mainly monoglucuronides, whereas very low levels 
of free EL were found122,123,125. High circulating levels of EL glucuronide with concomitant 
low levels of EL suggest a significant first-pass effect by glucuronidation. Glucuronidation 
occurs both in hepatocytes and enterocytes. Extensive glucuronidation results in variable and 
significant reductions in the oral bioavailability of EL, which may limit the biological 
properties of EL. However, the exact contributions from liver and intestine are poorly 
understood.  
Hence, a fundamental understanding of EL glucuronidation in the intestine and liver in 
vitro is essential to provide critical information regarding the oral absorption properties of EL, 
and also possibly to infer the potential for interactions. The in vitro evaluations of EL 
glucuronidation are obtained by the determination of intrinsic clearance (CLint), which directly 
measures the efficacy of enzymes to metabolize substrates146. Therefore, the in vitro 
evaluations of EL glucuronidation can provide a great understanding as to what extent EL 
undergoes intestinal and hepatic glucuronidation, which conjugation metabolites would be 
produced, and also the contributions from intestine and liver to EL glucuronidation. 
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2.7. Model System 
2.7.1. Microsomes 
Two basic strategies are often used for in vitro investigation of the metabolic profile of a 
drug: incubation with subcellular fractions, for example, microsomes, and incubation with 
differentiated cellular models such as primary cultures, encapsulated hepatocytes or tissue 
slices147. With intact cells, the plasma membrane, metabolic pathways, levels of physiological 
cofactors and coenzymes and active gene expression are reasonably well maintained for 
several hours/days in culture, which makes hepatocytes the closest model for in vivo studies147. 
However, microsomes are often the simple, affordable and best-characterized in vitro model, 
allowing an easy comparison of the metabolic profile of a compound across animal 
species147,148. Microsomes are easily prepared from tissues by homogenization and 
centrifugation, which contain almost only P450 and UGT enzymes. Microsomes can be stored 
at -80ºC for years with little or no loss of enzyme activities. As well, microsomes from 
different animal species are commercially available and are well standardized. The main 
drawback of microsomes is that the results obtained in vitro might be different from those 
obtained in vivo due to the enriched enzymes in microsomal fractions and the absence of other 
competing enzymes, but some equations exist to extrapolate in vitro data to in vivo 
pharmacokinetics148.  
 
2.7.1.1. Intrinsic clearance 
Intrinsic clearance (CLint) is the ability of each organ to remove drugs from the blood, 
which is independent of physiological factors such as blood flow and protein binding149. CLint 
directly measures the efficacy of enzyme to metabolize substrate146. Hence, determination of 
CLint in vitro will identify the contribution of the enzymes of each organ to the metabolism of 
the xenobiotics in vivo. Since CLint is the cornerstone to in vitro-in vivo extrapolation of 
metabolic data146, the comparison of intestinal CLint with hepatic CLint by the enzyme kinetic 
studies in vitro will, to a large degree, inform us of the first-pass glucuronidation of EL as well 
as the contribution of each organ to the first-pass metabolism of EL in vivo. 
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2.7.2. Human versus Rat Models 
Although humans are the most relevant system for evaluation, animal models are 
commonly used in the preclinical development of new drugs to predict the metabolic profile of 
new compounds in human. In comparison with other animal models, rat offers many 
advantages and is an excellent model for human diseases because of the well-characterized 
physiology that is more like the corresponding human conditions150. A volume of data has 
developed and numerous experimental protocols are well established, which enables an easier 
way to obtain information to design experiments, make comparisons between studies, and to 
extrapolate from in vitro to in vivo and from animals to humans. Furthermore, rat is frequently 
used as an experimental model to explore and evaluate the pharmacokinetic activities of 
lignans. Thus, conducting intestinal and hepatic glucuronidation of EL in rats is important to 
human health. The results will be considerably valuable for further future study and 
extrapolating to humans.  
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2.8. Hypothesis and Objectives 
SDG and its metabolites, especially EL, have received increasing interest for their 
putative health benefits. Once generated in the intestine, EL permeates the gastrointestinal 
barrier and undergoes conjugation with principally glucuronic acid before entering the 
systemic circulation. In human plasma and urine, the predominant conjugates of EL are 
mainly glucuronides, while very low levels of free EL were found. This suggests a significant 
first-pass glucuronidation occurring both in hepatocytes and enterocytes, which, to a large 
extent, results in variable and significant reductions in the oral bioavailability of EL. However, 
the exact contributions from liver and intestine are poorly understood. Hence, the purpose of 
the study is to provide an estimate of the relative contribution of the intestine and liver to 
presystemic glucuronidation of EL, which will provide a fundamental understanding regarding 
the oral absorption properties of EL. In vitro enzyme kinetic studies using intestinal and 
hepatic microsomal fractions from human and rat with determination of CLint allow the 
comparison of differences of EL glucuronidation between different organs and species. The 
aims of this project are accomplished by the following hypothesis and objectives: 
 
2.8.1. Hypothesis 
The intrinsic clearance (CLint) values from rat and human liver microsomes are greater 
than the values from intestinal microsomes. 
 
2.8.2. Objective 1 
Enzymatically generate EL glucuronides in rat liver microsomes, then purify and verify 
the glucuronides. 
 
2.8.3. Objective 2 
Validate the existing HPLC assay to allow for the quantitative determination of EL. 
 
2.8.4. Objective 3 
Conduct enzyme kinetic studies using rat and human hepatic and intestinal microsomal 
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fractions to determine and compare CLint of EL glucuronidation from each organ system. 
 38 
3. MATERIALS AND METHODS 
3.1. Chemicals 
Enterolactone (EL), uridine 5’-diphosphoglucuronic acid trisodium salt, D-saccharic acid 
1,4-lactone monohydrate, Trizma base, bovine serum albumin (BSA) and internal standard 
(umbelliferone) were obtained from Sigma-Aldrich Canada Ltd (Oakville, ON). A MilliQ 
Synthesis (Millipore, Bedford, MA) Water Purification system provided purified deionized 
water. All other chemicals used were analytical grade. Human liver and intestinal microsomes 
were purchased from XenoTech, LLC (Lenexa, KS). 
 
3.2. Experiment one: EL Glucuronide Synthesis and Characterization 
3.2.1. Preparation of Rat Liver and Intestinal Microsomes 
Male Wistar rats (N=6, weight range 250-300 g and age range 7-9 weeks) were obtained 
from the Animal Resources Centre (ARC), University of Saskatchewan. This work was 
approved by the University of Saskatchewan’s Animal Research Ethics Board, and adhered to 
the Canadian Council on Animal Care guidelines for humane animal use. 
 
3.2.1.1. Preparation of rat liver microsomes 
Rat liver and intestinal microsomes were prepared according to established protocols in 
our lab. Rat liver was removed promptly following isoflurane anesthesia of the rat and rinsed 
twice in ice water to remove excess blood. The liver was immediately immersed into liquid 
nitrogen and stored at -80ºC until preparation. Three grams of rat liver from three individuals 
were homogenized in 12 mL buffer (pH 7.4) containing 50 mM Tris buffer, 150 mM KCl, 0.1 
mM dithiothreitol, 1 mM ethylenediamine-tetraacetic acid (EDTA), 20% glycerol, 0.1 mM 
phenylmethylsulfonylflouride (PMSF) and double distilled water (ddH2O). The liver 
homogenate was then ultracentrifuged at 9,184 × g for 30 min. The supernatant was 
transferred and ultracentrifuged at 112,504 × g for 30 min. The microsomal pellet was washed 
with 150 mM KCl in ddH2O, and then ultracentrifuged at 112,504 × g for another 30 min. 
Microsomal pellets were resuspended in 0.25 M sucrose solution. The rat liver microsomes 
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were stored at -80ºC. The total protein concentration was determined by BioRad RC DC 
Protein Assay Kit (Bio-Rad Laboratories Ltd., Mississauga, ON) using bovine serum albumin 
(BSA) as a standard. 
 
3.2.1.2. Preparation of rat intestinal microsomes 
To compare the metabolic activities of different sections of rat small intestine, intestinal 
microsomes extracted from duodenum, jejunum and colon were prepared. Tissue consisting of 
the proximal duodenum, jejunum and colon were removed from anaesthetized rats (n=2). The 
intestinal sections were instantly placed in ice-cold buffer solution A (KCl 1.5 mM, NaCl 96 
mM, sodium citrate 27 mM, KH2PO4 8 mM, Na2HPO4 5.6 mM, pH to 7.4)151 to flush out 
intestinal contents. The remaining intestinal sections were dissected longitudinally and 
spreaded on an ice-cold glass plate with the mucosal side upwards. The mucosa was then 
gently scraped using a microscope slide. The scraped mucosa was homogenized in solution B 
(histidine 5 mM pH 7.0, sucrose 0.25 M, NaEDTA 0.5 mM, pH to 7.4) by sonication, 7 cycles, 
10 seconds each (wattage=4). The homogenate was then centrifuged at 15,000 × g for 10 min. 
The supernatant was collected, and 1.25 mL of 52 mM CaCl2 for each 7 mL supernatant was 
added. The tubes containing microsomes were gently shaken for 10 s and then allowed to 
stand for 15 min on ice. Fractions were then centrifuged at 25,000 × g for 10 min152. Pellets 
were resuspended in 0.25 M sucrose/0.02 M Tris buffer. The rat liver and intestinal 
microsomes were stored at -80ºC. The total protein concentration was determined by BioRad 
RC DC Protein Assay Kit using BSA as a standard. 
 
3.2.2. Enterolactone Glucuronide Synthesis 
EL glucuronide (EL-Glu) was enzymatically synthesized by incubating with pooled 
human and rat liver and intestinal microsomes, respectively, at room temperature for 22 h. The 
incubation experiment was conducted basically as described in a previous study124, while 
some experimental conditions were changed. Briefly, the incubation mixture (1 mL) consisted 
of 5 mM uridine 5’-diphosphoglucuronic acid trisodium salt, 5 mM MgCl2, 5 mM D-saccharic 
acid 1,4-lactone monohydrate, 100 mM Trizma base (adjusted with HCl to pH 7.4), 2 mM EL 
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and microsomal protein (3.1 mg/mL). The reaction was initiated by adding uridine 
5’-diphosphoglucuronic acid trisodium salt. At the end of the incubation methanol (2 volumes) 
was added to terminate the reaction and precipitate proteins. After centrifugation of the 
mixture for 10 min at 10,000 × g in an Eppendorf microcentrifuge (Model 5417C, Brinkmann 
Instruments, Westbury, NY), the supernatant was concentrated by rotary evaporation and 
made up to its original volume. 
 
3.2.3. Purification of EL Glucuronide Conjugates 
The mixture of EL-Glu generated from rat liver microsomes was purified by HPLC 
Waters 600 system. The HPLC system consisted of Waters Model 600 solvent delivery system, 
Model 2996 photodiode Array Detector with the fixed wavelength at 280 nm, Model 717 plus 
autosampler. All chromatographic separations were carried out on a reversed-phase 
semi-preparative column (Allsphere ODS-2 300×10 mm I.D., 5 µm particle size). The 
analytes were eluted under gradient mode with mobile phase consisting of water with 0.1% 
formic acid (component A) and acetonitrile with 0.1% formic acid (component B) in different 
ratios delivered at a flow rate of 3 mL/min. The gradient consisted of 85:15 component A: 
component B from 0 to 12 min, an increasing gradient from 15% to 50% component B and 
from 50% to 90% between 12 and 14 min and then 90% between 14 and 18 min, with a 
decreasing gradient from 90% to 15% component B from 18 to 20 min and a return to 85:15 
component A: component B between 20 and 25 min. Fractions containing glucuronide at the 
desired retention time were collected automatically by Waters Fraction Collector, and solvents 
were removed by rotary evaporation. 
 
3.2.4. Characterization of EL Glucuronide 
Liquid chromatography-mass spectrometry (LC-MS) was used to verify and confirm the 
formation and structure of the purified fractions containing EL glucuronide. The LC-MS/MS 
analysis was conducted on a Hybrid Triple Quadrupole/Linear Ion Trap mass spectrometer 
(AB Sciex 4000 QTRAP, MS/MS system, Applied Biosystems Inc., Foster City, CA) fitted 
with Turbo V electrospray ionization (ESI) source in the negative mode, coupled with Agilent 
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Technologies 1100 Series LC which consisted of a binary pump and autosampler. The 
chromatographic separation was performed on a Waters Symmetry Reverse-Phase C18 
column (150×4.6 mm I.D., 5 µm particle size). The gradient was the same as described above. 
The flow rate was delivered at 1 mL/min. The MS parameters were optimized for EL-Glu as 
follows: declustering potential (DP) -90 V, collision energy (CE) -36 V, Collision Cell Exit 
Potential (CXP) -23 V. The ion source parameters were curtain gas (CRU) 10 V; ion spray 
voltage (IS) -4500 V; temperature (TEM) 400; ion source gas 1 (GS1), 40 psi; ion source gas 
2 (GS2), 40 psi; collision activated dissociation (CAD) medium; entrance potential (EP) -10 V. 
The fragmentation transitions for multiple reaction monitoring (MRM) were mass to charge 
ratio (m/z) 473.0→297.0 and 473.0→175.0.      
 
3.3. Experiment Two: HPLC Method 
A reliable and simple HPLC method for the quantitative determination of flaxseed 
lignans was established in our lab102. Hence, a partial HPLC method validation was conducted 
to allow for the quantitative determination of EL in this study. 
 
3.3.1. Instrumentation and Chromatographic Conditions 
The HPLC (Agilent Technologies, Mississauga, ON) system consisted of a Series 1200 
quaternary pump (G1311A) with online degasser (G1322A), autosampler (G1329A) and 
fluorescence detector (G1321A). Excitation wavelength was set at 277 nm and emission 
wavelength at 617 nm. Processed samples (50 µL) were injected onto a Waters Symmetry 
Reverse-Phase C18 column (150×4.6 mm I.D., 5 µm particle size). The analytes were eluted 
under gradient mode with mobile phase consisting of water with 0.1% formic acid (component 
A) and acetonitrile with 0.1% formic acid (component B) in different ratios delivered at a flow 
rate of 1 mL/min. The gradient consisted of 85:15 component A: component B from 0 to 12 
min, an increasing gradient from 15% to 50% component B and from 50% to 90% between 12 
and 14 min and then 90% between 14 and 18 min, with a decreasing gradient from 90% to 
15% component B from 18 to 20 min and a return to 85:15 component A: component B 
between 20 and 25 min.  
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3.3.2. Validation of HPLC Method 
HPLC method validation procedures were performed based on FDA guidelines. 
Specificity was assessed by analyzing pooled human liver microsomes (HLM), human 
intestinal microsomes (HIM), rat duodenum microsomes (RDM), rat jejunum microsomes 
(RJM), rat colon microsomes (RCM) and six different rat liver microsomes (RLM), whose 
preparations were supplemented only with internal standard (umbelliferone) to determine the 
absence of endogenous substances with similar retention time as EL and/or EL-Glu.  
The sensitivity of the method was evaluated by determination of the limit detection (LOD) 
and the lowest limit of quantification (LLOQ). LOD was defined as the lowest detectable 
concentration, considering the signal-to-noise ratio of 3. The lowest limit of quantification 
(LLOQ) was the lowest concentration of the standard curve that gave acceptable accuracy and 
precision. Accuracy (%) was expressed as [(calculated amount/predicted amount)*100] with 
acceptable limits at 15% except at LLOQ, where it should not deviate by more than 20%. 
Precision was expressed as % relative standard deviation (RSD) with acceptable level at 15% 
of the coefficient of variation (CV) except at LLOQ, where it should not exceed 20% of CV. 
The intra-day accuracy and precision were evaluated by analyzing six replicates of quality 
control (QC) samples (low, medium and high concentrations of quality controls) on a single 
day. The inter-day accuracy and precision were determined from the same QC samples on 
three different days.  
The linearity of the method was assessed by processing a 6-point calibration curve on 
several different days. The ratios of the peak areas of analytes and the internal standard were 
plotted against the nominal concentrations of the analytes. A linear least-squares regression 
analysis using 1/X2 as weighting factor was conducted to determine slope, intercept and 
coefficient of determination (r2) to demonstrate linearity of the method.  
 
3.4. Experiment Three: Enzyme Kinetic Analysis 
Enzyme kinetics were conducted using pooled HLM, HIM, RLM, RJM and RCM, 
respectively. Pooled human liver (pool of 50) and intestinal microsomes (pool of 13) from 
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mixed gender were purchased from XenoTech, LLC (Lenexa, KS). Human intestinal 
microsomes were prepared from duodenal and jejunal tissues. Pooled rat liver (pool of 3) and 
jejunum and colon (pool of 2) from male gender were extracted based on established protocols 
in our lab. Comparison of EL glucuronidation between species and tissues was assessed by 
determination of intrinsic clearance (CLint) in intestinal and liver microsomes. CLint (as a 
measure of the maximal efficacy of enzyme to metabolize substrate) was determined by the 
substrate depletion method, in which the depletion of substrate was monitored as a function of 
time153.  
The incubation mixture consisted of (at their final concentrations): microsomes (0.5 
mg/mL), 5 mM MgCl2, 5 mM D-saccharic acid 1,4-lactone monohydrate, 100 mM Trizma 
base (adjusted with HCl to pH 7.4). A range of final EL concentrations (10-500 µM) was 
incubated with HLM and RLM, respectively, while EL concentrations (10-300µM) were 
incubated with HIM. The total incubation volume for all of three incubations was 1.5 mL. EL 
concentrations (1.5-100 µM) were used when incubating with RJM and RCM with a total 
volume of 1.0 mL. Trizma base (pH 7.4) containing uridine 5’-diphosphoglucuronic acid 
trisodium salt (5 mM final concentration) preincubated at 37ºC for 5 min in a shaking water 
bath was used to initiate the reaction. At multiple incubation time points, aliquots (0.2 mL) in 
the incubations containing HLM, HIM and RLM were withdrawn and 20 µL internal standard 
(1.23 mM umbelliferone) in acetonitrile was added to the aliquots. At equivalent incubation 
time points, aliquots (130 µL) in the incubations containing RJM and RCM were withdrawn 
and 13 µL of internal standard in acetonitrile was added. Subsequently, the aliquots were 
immersed into the liquid nitrogen immediately to terminate the reaction. After thawing on the 
ice, the mixture was centrifuged at 10,000 × g for 10 min in an Eppendorf microcentrifuge 
(Model 5417C, Brinkmann Instruments, Westbury, NY). 50 µL of the supernatant (triplicate) 
for HLM, HIM and RLM incubations as well as duplicates (50 µL) for RJM and RCM 
incubations was injected on the Waters Symmetry Reverse-Phase C18 column (150×4.6 mm 
I.D., 5 µm particle size) for the immediate HPLC analysis of EL. Heated microsomes, no EL 
and no uridine 5’-diphosphoglucuronic acid trisodium salt incubation reactions were used as 
negative controls.     
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3.5. Data Analysis 
To determine CLint, kinetic parameters in microsomal preparations were estimated with the 
methods reported by both Obach and Reed-Hangen and Komura and Iwaki 154,155. 
Analyte/internal standard peak area were determined and normalized to the ratio obtained at 
time, t=0, which represents 100%. A plot of natural log EL percent remaining versus time was 
constructed to calculate the substrate depletion rate constant (kdep) (the slope of each linear line) 
for each EL concentration. If substrate decline demonstrated nonlinearity on log percentage 
remaining versus time curves, only those initial time points wherein log linearity was observed 
were used to determine depletion rate constants. The Km and kdep([S]→0) values were determined 
by plotting depletion rate constants (kdep) versus various initial EL concentrations by a 
nonlinear least squares regression analysis with Prism 4.0 software (GraphPad Prism, San 
Diego, CA, USA) using the following equation: 
 
kdep = kdep([ S ]→0 ) •(1−
[ S ]
[ S ] + Km
)  
 
where kdep is the apparent first-order rate constant of substrate depletion, [S] is the substrate 
concentration and kdep([S]→0) is the theoretical maximum consumption rate constant at an 
infinitesimally low substrate concentration and Km is the Michaelis-Menten constant. The 
intrinsic clearance at an infinitesimally low substrate concentration (CLint, app([S]=0)) was 
calculated by dividing kdep([S]→0) by the microsomal protein concentration used. Vmax was 
derived from generated Km and CLint, app([S]=0). 
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4. RESULTS 
4.1. EL Glucuronide Synthesis with Rat and Human Microsomes 
EL glucuronide was enzymatically generated by incubation with rat liver and intestinal 
(duodenum, jejunum and colon) microsomes, human liver and intestinal microsomes, 
respectively, at room temperature for 22 h as most of the EL was converted to EL glucuronide 
in this time frame. HPLC (Waters 600 system, semi-preparative column) analysis of EL 
glucuronide from rat liver microsomes (RLM) resulted in the appearance of a single product 
peak. The retention time for EL glucuronide (EL-Glu) was 14.1 min, and some EL was 
unreacted and observed in the incubation mixtures (Figure 4.1A). After purification of EL-Glu 
from RLM by semi-preparative HPLC, three milligrams of EL-Glu was collected and no EL 
was detected in this sample (Figure 4.1B). However, I found that the peak shape of purified 
EL-Glu was not symmetrical, indicating the presence of more than one form of EL-Glu. 
Accordingly, LC-MS/MS was used to identify and confirm the formation and structures of the 
purified fractions containing EL-Glu. MS analysis suggested that the glucuronide for EL from 
RLM predominantly occurred as the monoglucuronide with an m/z of 473. The optimized 
fragments for EL monoglucuronide were 297 and 175, which corresponded with the cleavage 
of the bond between EL and glucuronic acid (Figure 4.2).  
Multiple Reaction Monitoring (MRM) was also employed to further oversee the 
formation of EL monoglucuronide from each tissue and species. According to two peaks 
observed with very close retention times around 9 min, the data suggested the formation of 
two monoglucuronides for EL incubated with RLM (Figure 4.3). Interestingly, only one peak 
was observed by MRM for EL-Glu from rat intestinal microsomes (Figure 4.4A-C), human 
liver and intestinal microsomes (Figure 4.4D-E). In addition, preliminary microsomal 
incubation results showed that colon made a greater contribution to EL glucuronidation than 
jejunum, but both tissues were dramatically greater than that of duodenum in rat intestine. 
Hence, only colon and jejunum were used to further explore the enzyme kinetics for EL 
glucuronidation in rat intestine. Human liver produced EL-Glu more efficiently than human 
intestine. 
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Figure 4.1 Representative HPLC chromatograms of unpurified EL glucuronide (A) and 
purified EL glucuronide (B) generated from rat liver microsomes. Conditions: Waters 600 
HPLC system; reversed-phase semi-preparative column (300 × 10 mm I.D., 5 µm particle 
size); component A: water with 0.1% formic acid, component B: acetonitrile with 0.1% formic 
acid; detection wavelength at 280 nm.  
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Figure 4.2 LC-MS analysis of proposed EL glucuronide (m/z 473) formed from rat liver 
microsomes obtained in negative electrospray ionization (ESI) mode 
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Figure 4.3 Multiple reaction monitoring chromatograms of unpurified EL glucuronide (A) and 
purified EL glucuronide (B) generated from rat liver microsomes (RLM) 
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Mono EL-Glu from RLM 
Unreacted EL 12.49 min 
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Figure 4.4 Multiple reaction monitoring analysis of EL glucuronide incubated with rat 
duodenum microsomes (RDM) (A), rat jejunum microsomes (RJM) (B), rat colon microsomes 
(RCM) (C), human liver microsomes (HLM) (D) and human intestinal microsomes (HIM) (E) 
Mono EL-Glu from HIM 
Unreacted EL 12.08 min 
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4.2. HPLC Method Validation for EL  
A HPLC method was validated for the quantitative determination of EL in RLM. Figure 
4.5 represented HPLC chromatograms for blank rat liver microsomes and EL, and its internal 
standard (umbelliferone) in RLM. No endogenous substances were found in RLM, RCM, 
HLM and HIM that interfered with EL. The chromatographic conditions gave retention times 
for internal standard (umbelliferone) and EL as 6.8 and 12.0 min, respectively. The recovery 
of EL was 104.9, 110.6 and 109.8% at LQC, MQC and HQC, respectively. The lower limit of 
quantification (LLOQ) for EL was 41.7 ng/mL. Table 4.1 and Table 4.2 summarize the intra- 
and interday precision and accuracy data. Overall, the intra- and interday precision and 
accuracy for EL of this HPLC method were ≤ 10%, suggesting the method was both precise 
and accurate to quantitatively determine EL in rat and human liver and intestinal microsomes. 
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Figure 4.5 Representative HPLC chromatograms of blank rat liver microsomes (A) and rat 
liver microsomes spiked with internal standard umbelliferone (100µg/mL, 6.8 min) and EL (4 
µg/mL, 12.0 min) (B). Conditions: Agilent 1200 HPLC system; Waters Symmetry 
reversed-phase C18 analytical column (150 × 4.6 mm I.D., 5 µm particle size); component A: 
water with 0.1% formic acid, component B: acetonitrile with 0.1% formic acid; excitation 
wavelength at 277 nm and emission wavelength at 617 nm. 
Umbelliferone 6.8 min 
EL 12.0 min 
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Table 4.1 Intraday assay precision and accuracy for EL in rat liver microsomes (N=6) 
QC levels Precision                Accuracy 
LLOQ   
Day 1 2.7 92.7 
Day 2 1.6 101.4 
Day 3 4.8 101.1 
LQC   
Day 1 4.4 90.0 
Day 2 4.3 100.6 
Day 3 2.8 95.4 
MQC   
Day 1 3.3 94.7 
Day 2 2.2 106.5 
Day 3 4.0 100.2 
HQC   
Day 1 1.5 93.9 
Day 2 2.8 102.3 
Day 3 3.1 97.0 
* Precision is expressed as CV% = standard  deviation
mean
×100%  
* Accuracy is calculated as mean determined concentration
actual concentration
×100%  
* LLOQ for EL is 41.7 ng/mL; LQC for EL is 150 ng/mL; MQC is 4000 ng/mL and HQC is 
8000 ng/mL 
  
 
Table 4.2 Interday assay precision and accuracy for EL in rat liver microsomes (N=6) 
QC levels Precision Accuracy 
LLOQ 3.9 98.4 
LQC 5.0 95.4 
MQC 4.9 100.5 
HQC 3.4 97.8 
* Precision is expressed as CV% = standard  deviation
mean
×100%  
* Accuracy is calculated as mean determined concentration
actual concentration ×100%
 
* LLOQ for EL is 41.7 ng/mL; LQC for EL is 150 ng/mL; MQC is 4000 ng/mL and HQC is 
8000 ng/mL  
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4.3. In Vitro Hepatic and Intestinal Microsomal Intrinsic Clearance of EL 
The in vitro CLint values of EL glucuronidation were examined using RLM, RJM and 
RCM extracted in our lab and commercial sources of HLM and HIM (XenoTech, LLC) by the 
substrate depletion approach154 (Table 4.3). Control assays conducted with heated microsomes 
and without microsomes and uridine 5’-diphosphoglucuronic acid trisodium salt exhibited no 
substrate depletion over time. The relationships between the first-order constants for substrate 
depletion (termed kdep) and EL concentrations for EL glucuronidation were shown in Figure 
4.6. Typical examples of the process to generate kdep value were exhibited in Appendix I. kdep 
values for each substrate concentration for rat and human liver and intestinal microsomes were 
summarized in Appendix I. The in vitro CLint values for EL glucuronidation determined with 
RLM and HLM were much greater than those for intestinal microsomes, and the HLM (1.18 
mL/min/mg) gave the highest value. RJM and RCM gave comparable CLint values; on the 
other hand, they were considerably lower than HIM (Figure 4.7A). Similar trends also applied 
to Vmax values, nonetheless, RLM showed the highest Vmax value (Figure 4.7B). The Km 
values for EL glucuronidation evaluated using rat microsomes were significantly larger than 
human microsomes among which RCM had the highest Km value as 45.9 µM. Rat intestinal 
microsomes generated greater Km values than rat liver microsomes, the results of which were 
in agreement with that of human (Figure 4.7C). 
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Table 4.3 CLint and Michaelis-Menten constants of EL glucuronidation by rat and human 
liver and intestinal microsomes 
Microsomes 
 
CLint 
mL/min/mg 
95% CI for 
CLint  
Km 
µM 
95% CI 
for Km 
Vmax 
nmol/min/mg 
RLM 
RJM 
RCM 
HLM 
HIM 
1.00 ± 0.1   
0.05 ± 0.003 
0.058 ± 0.003 
1.18 ± 0.09 
0.31 ± 0.027 
0.77 - 1.24 
0.042 - 0.058 
0.050 - 0.066 
0.97 - 1.40 
0.25 - 0.37 
25.6 ± 5.07 
31.6 ± 7.72 
45.9 ± 11.4 
8.91 ± 1.07 
12.6 ± 1.84 
13.2 - 38.0 
12.7 - 50.4 
16.6 - 75.1 
6.44 - 11.4 
8.36 - 16.9 
25.7 
1.58 
2.65 
10.6 
3.90 
Different range of EL concentrations were incubated with liver and intestinal microsomes 
from human and rat (0.5 mg/mL) for 30 min. CLint, intrinsic clearance; Km, the substrate 
concentration at half maximum velocity; Vmax, maximum velocity; RLM, rat liver microsomes 
(n=3); RJM, rat jejunum microsomes (n=2); RCM, rat colon microsomes (n=2); HLM, human 
liver microsomes (n=50); HIM, human intestinal microsomes (mixture of duodenal and jejunal 
tissues, n=13); ±, standard error of the calculated kinetic parameters; CI, confidence intervals. 
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Figure 4.6 Plots of in vitro depletion rate constants (kdep) (min-1) versus EL concentrations 
(µM) for EL glucuronidation by rat liver microsomes (A), rat jejunum microsomes (B), rat 
colon microsomes (C), human liver microsomes (D), and human intestinal microsomes (E). 
Substrate depletion rate constant (kdep) for each substrate concentration was equal to the slope 
of the linear line from a plot of ln analyte peak area percentage remaining (normalized to the 
initial peak area obtained at t=0.) versus time. Refer to Appendix I for all kdep values for 
various EL concentrations for different organs from different species. 
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Figure 4.7 The CLint (A), and Michaelis-Menten constants, Vmax (B) and Km (C), for EL 
glucuronidation by rat liver microsomes (RLM, n=3), rat jejunum microsomes (RJM, n=2), rat 
colon microsomes (RCM, n=2), commercial human liver microsomes (HLM, n=50) and 
commercial intestinal microsomes (HIM, n=13) 
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5. DISCUSSION 
The aim of the project was to quantitatively make a comparison of the intestinal and 
hepatic glucuronidation of enterolactone (EL) derived from flaxseed lignans by the 
determination of intrinsic clearance (CLint) using the substrate depletion approach. Human and 
rat were employed to define the interspecies differences of EL glucuronidation to reduce the 
uncertainties of extrapolating pharmacokinetic data from rat studies to humans. The 
characterization of EL pharmacokinetics (e.g. metabolism) is critical to evaluate the exposure 
dose, susceptibility of low-dose exposure caused by first-pass metabolism, as well as 
drug-lignan interactions resulting from coadministration of flaxseed lignans with drugs and/or 
other Natural Health Products (NHPs). To accomplish this purpose, three experiments were 
carried out for this research project.    
 
5.1. EL Glucuronide Synthesis and Characterization 
My first objective was to enzymatically synthesize EL glucuronides (EL-Glu) in vitro 
and verify the structures by LC-MS/MS to ensure the formation of EL glucuronides, which 
was the foundation of enzyme kinetic studies for EL glucuronidation. Based on the literature, 
the suggested incubation time for EL and ED were 8 h and 24 h at 25ºC, respectively124. In 
order to confirm 8 h was sufficient to convert EL to EL-Glu, I made a comparison of the 
incubation reaction for EL at 8 h, 22 h and 24 h, respectively, and found 22 h was long enough 
for the biotransformation of EL into EL-Glu, while the reaction was not complete at 8 h (data 
not shown). As 37ºC, representing the body temperature, is often used as the temperature for 
enzyme incubation, a comparison was made between 25 and 37ºC to assess the appropriate 
temperature for the incubation. No significant difference existed between these two 
temperatures; while 25ºC was chosen considering that this condition was easier to control.  
After incubation of EL with rat liver microsomes (RLM) and purification of the 
generated glucuronides, a single peak at 14.1 min was observed by semi-preparative 
chromatography (4.1B). The asymmetrical peak suggested that more than one form of 
glucuronide was possibly produced. This was further substantiated by LC-MS/MS. Two peaks 
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whose retention time were close to 9 min, were determined by multiple reaction monitoring 
(MRM) mode, indicating two monoglucuronides were generated for EL incubating with RLM. 
As EL is not a symmetric molecule, glucuronidation of the different phenol groups would be 
expected to produce isomers. This result was consistent with the glucuronidation of EL in 
rabbit and/or rhesus monkeys liver microsomes, suggesting that EL was conjugated to either 
phenolic hydroxyl and was able to form two phenol β-O-glucuronides115,124. Hence, the 
generated EL glucuronides from RLM were actually a mixture of two monoglucuronides, 
which can barely be separated by HPLC124 or the LC-MS in my project. It was interesting that 
a single peak was detected by MRM for EL-Glu generated from rat intestinal microsomes, 
human liver and intestinal microsomes, implying only one or a major monoglucuronide was 
produced by those microsomes, which was different from the results from RLM. This might 
be due to the interspecies (rat versus human) as well as interorgan (liver versus intestine) 
differences, of which the types and content of UGT might be distinct, resulting in the varying 
levels of EL glucuronidation. 
 
5.2. Substrate Depletion Approach 
Traditionally, the kinetic behavior of an enzyme is often characterized by monitoring 
product formation rates at various substrate concentrations153. To fulfill this, metabolite 
concentrations in in vitro matrices have to be measured by analytical methods, requiring that 
metabolites have been definitively identified and authentic standards prepared to construct 
calibration curves154. However, these are not always readily and/or feasibly obtained. In my 
experiment, EL-Glu generated from RLM have been identified by LC-MS/MS and purified by 
HPLC system. Nevertheless, the purity of the fractions cannot be exactly determined to ensure 
highly purified EL-Glu to be used as authentic standards. Furthermore, the enzymatic 
synthesis method was costly both in time and money to accumulate sufficient amounts of 
purified EL-Glu to be used as standards because of the complex and time-consuming 
production process and the expensive incubation materials (EL and uridine 
5’-diphosphoglucuronic acid trisodium salt). Therefore, the substrate depletion approach that 
monitors depletion of a substrate as a function of time was used to determine the kinetic 
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parameters of the UGT. Nath and his coworkers have demonstrated that kinetic parameters 
obtained from the substrate depletion approach can be meaningfully compared with those 
obtained by measuring product formation153. 
It has to be noted that the substrate depletion approach also possesses some practical 
limitations. One of the significant shortcomings of the substrate depletion approach is that the 
enzyme kinetics of formation of individual products are possibly missed, resulting in the 
overestimation of the individual intrinsic clearance (CLint) and/or Km values. The obtained 
values represent a conglomeration of all CLint or Km values for individual metabolic 
pathways154. For EL glucuronidation, EL was incubated with microsomes that primarily 
contained P450 enzymes and UGT; however, only cofactor uridine 5’-diphosphoglucuronic 
acid trisodium salt was added into the incubation system for the conjugative reaction, which 
theoretically should yield only EL-Glu. This supposition was corroborated by the 
experimental results with HPLC analysis, which showed the appearance of a single product 
peak; control assays conducted without cofactor uridine 5’-diphosphoglucuronic acid 
trisodium salt demonstrated no product formation. Additionally, LC-MS confirmed the 
formation as well as the structure of EL-Glu. Therefore, the substrate depletion approach can 
be used to estimate the enzyme kinetic parameters for EL glucuronidation. 
An important constraint when using the substrate depletion approach is the use of time 
points for calculation of kdep where no more than 10% of the substrate has been consumed; 
otherwise, the estimated kdep values will be associated with significant error, which in turn 
results in Km and Vmax values with significant error153. However, a simulation study indicated 
only 15% error in the estimated kinetic parameters when the data used to obtain kdep included 
time points where 50% of the substrate has been consumed153. In my study, we had to include 
time points with ~50% (and sometimes greater) EL depletion to generate parameter estimates 
following the nonlinear regression analysis of the data. Hence, our calculated kdep values and 
reported Km values have error associated with their determination (> 15%), and the calculated 
CLint and Vmax values are likely greater than their true values153. Some experimental conditions 
should be carefully considered to improve the substrate depletion approach in the future. As a 
large portion of substrate (~50%) is potentially depleted, the microsomal protein content and 
the incubation time should be carefully optimized to decrease the rate of substrate 
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consumption, thus to minimize the errors of calculated kinetic parameters due to the over 
depletion of substrate.       
   
5.3. Interorgan Differences on EL Glucuronidation 
5.3.1. Human Liver versus Human Intestine 
Organ and species differences in CLint and Michaelis-Menten parameters (Vmax and Km) 
for in vitro glucuronidation of EL were investigated (Table 4.3). The results were consistent 
with the reports by the other, for which the microsomal UGT activities in the small intestine 
and /or colon were lower than that in the liver156. My study showed that all the hepatic CLint 
values as well as glucuronidation rates were greater than that of the intestine, suggesting liver 
is predominant and more efficiently transforms EL into glucuronides as compared with the 
intestine. An understanding of the level of expressed UGT in the liver and intestine is 
necessary to further understand the relationship between hepatic and intestinal enzyme levels 
and glucuronidation157.  
Currently, 15 human enzymes and 14 rat enzymes are known to exhibit significant 
conjugative activity towards endogenous and xenobiotic compounds119,156. A significant 
number of studies have reported the expression and localization of UGT mostly by utilizing 
reverse transcription-polymerase chain reaction (RT-PCR) or Northern blotting 
analysis156,158-162. Ten UGT are extensively expressed in human liver with large interindividual 
variability, including 5 UGT1 isoforms (UGT1A1, 1A3, 1A4, 1A6 and 1A9) and 5 UGT2 
isoforms (UGT2B4, 2B7, 2B10, 2B15 and 2B17), and the sum of the UGT2B mRNA levels 
was higher than that of UGT1A mRNA levels160 (Table 5.1). An extremely high expression of 
UGT2B4, 2B10, 2B15, 2B7 was found, followed by some UGT1 members including 
UGT1A1, 1A6 and 1A9121,158-160.  
Expression of UGTs in the human small intestine and colon is less abundant relative to 
the liver. Several UGT isoforms such as UGT1A1, 1A5, 1A10, 2B7, 2B15 and 2B17 are 
expressed, whereas UGT1A10 and 2B17 are found primarily in the intestine158. UGT1A8 is 
expressed in the intestine and colon but not liver158,163. Hence, the various types and 
considerable content of UGT1A and UGT2B families in human liver help explain why hepatic 
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glucuronidation of EL was significantly larger than that in the human intestine. In addition to 
the UGT activity, the concentration of its significant cofactor 5'-diphosphoglucuronic acid 
(UDPGA) has been measured in human liver and intestinal mucosa, where it was found that 
the concentration of UDPGA in the liver was 279 nmol/g, over 14 times higher than that in the 
intestinal mucosa (19.3 nmol/g)164. This evidence further demonstrates the overall hepatic 
glucuronidation activity is much greater than that in the intestine.  
However, it is noteworthy the CLint value of human intestine (CLint=0.309) was 
approximately one third of the value of human liver (CLint=1.18), suggesting human intestine 
makes an important contribution to EL glucuronidation and may exert a significant influence 
on the first-pass metabolism of EL. In a study evaluating the glucuronidation of EL at 100 µM 
with 9 expressed human UGT isoforms (UGT1A1, 1A3, 1A4, 1A6, 1A8, 1A9, 1A10, 2B7, 
2B15), only human UGT1A4 and UGT1A6 failed to catalyze EL glucuronidation, while 
UGT2B7 and UGT1A9 showed the highest catalytic activities, followed by 1A8 and 1A10, 
with minor contributions from UGT1A1, 1A3 and 2B15115. From the foregoing reports, it is 
known UGT1A9 and UGT2B7 are substantially expressed in the liver, whereas UGT1A8 and 
UGT1A10 are specific for intestine, which implies liver, as expected, is the primary organ to 
transform EL into glucuronides; however, the UGT isoforms such as UGT1A8 and UGT1A10 
in the intestine also play a crucial role in EL glucuronidation.  
The human intestinal microsomes used in my project were prepared from duodenal and 
jejunal tissues. The distribution of UGT is not well characterized along the small intestine in 
the literature. Nevertheless, based on the catalytic UGT activities examined in the small 
intestine and liver using 18 substrates, it was suggested that the catalytic activities were 
greatest in the jejunum, and the proximally located duodenum showed higher catalytic 
activities than the distally located ileum in 16 substrates161. Therefore, the combination of 
duodenum and jejunum is able to largely represent the general UGT activity in human small 
intestine. Furthermore, the finding that the catalytic activities using 18 substrates in the 
jejunum were universally greater than those found in liver suggested that extrahepatic 
glucuronidation in small intestine can function to complement hepatic glucuronidation161. 
Although the liver has been long considered as the major organ responsible for the xenobiotic 
glucuronidation, the small intestine, as the first site of oral exposure, could possibly alter 
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first-pass metabolism and affect bioavailability in humans. Thus, omitting the role of human 
intestinal glucuronidation will underestimate overall metabolic clearance165.   
 
5.3.2. Rat Liver versus Rat Intestine 
In rat, 7 functional members of UGT1 family and 7 UGT2 isoforms have been 
identified119,166 (Table 5.2). However, the tissue distribution of rat UGT1 and UGT2 isoforms 
has not been thoroughly examined, especially UGT2 family. Similar to human liver, several 
UGT2B members are mainly expressed in rat liver including UGT2B1, 2B2, 2B3, 2B6 and 
2B12167,168. In contrast to rat UGT2B family, of the seven members of the UGT1A family, 
only UGT1A1, 1A5 and 1A6 are detected at an appreciable level in rat liver167,169. In my 
project, the estimated hepatic CLint was ten times higher than that of rat intestinal microsomes 
including both rat jejunum and colon microsomes. The substantial expression of UGT in rat 
liver may explain the large amount of glucuronidation by the liver. Another study that 
evaluated the glucuronidation of several aglycones in small intestinal microsomes of rats and 
compared these with glucuronidation in liver microsomes also suggested the intestinal 
activities were much lower than in liver, representing 5-15% of hepatic activities170, which 
was consistent with my results. Moreover, the UDPGA concentrations in rat liver and small 
intestine were 400 and 100 nmol/g tissue, respectively171, providing supportive evidence that 
rat liver is more competent to mediate glucuronidation than small intestine.   
 Multiple UGT1 family members are expressed in intestine, with UGT1A2, 1A3 and 
1A7 as the predominant isoforms167,169(Table 5.2). Unlike with the UGT1 family, few UGT2B 
subfamily members are detected, while only UGT2B8 is the principal isoform expressed in 
duodenum167,168. Quantitative evaluation of RNA levels by Northern blot revealed gradients of 
expression, with highest UGT1A mRNA levels found in duodenum and decreasing levels in 
the distal small and large intestine169. The aforementioned data suggest rat duodenum 
contributes more to UGT activities than other sections in intestine. However, this is somewhat 
against my finding that rat duodenum made the least contribution to EL glucuronidation. This 
discrepancy might be due to the differences in tissue collection. Alternatively, the isoforms 
responsible for EL glucuronidation might demonstrate higher expression in the colon. The 
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CLint for EL glucuronidation was comparable between rat jejunum and colon (0.0500 and 
0.0578, respectively), which suggests similar UGT activity for EL glucuronidation might exist 
between rat jejunum and colon.  
  
 66 
Table 5.1 Quantitative determination for human UGT (Adapted from Ohno158) 
    Tissue 
UGT 
Liver 
(GAPDH 94.8 ± 0.0) 
Small intestine 
(GAPDH 124 ± 0.7) 
Colon 
(GAPDH 59.4 ± 1.0) 
1A1 1430 ± 26.4 582 ± 9.7 372 ± 9.4 
1A3 131 ± 5.4 24.4 ± 1.5 N.D. 
1A4 618 ± 3.8 N.D. N.D. 
1A5 8.59 ± 2.99 71.6 ± 4.1 45.6 ± 13.4 
1A6 468 ± 5.4 94.5 ± 2.7 N.D. 
1A7 5.07 ± 4.00 26.3 ± 1.0 25.1 ± 4.0 
1A8 N.D. 70.0 ± 3.5 117 ± 8.4 
1A9 1210 ± 9.7 38.3 ± 4.4 50.0 ± 2.7 
1A10 N.D. 968 ± 28.4 754 ± 32.4 
2B4 37,900 ± 711 N.D. N.D. 
2B7 4220 ± 12.7 1930 ± 7.4 2210 ± 30.3 
2B10 3380 ± 92.7 N.D. N.D. 
2B11 N.D. N.D. N.D. 
2B15 18,500 ± 285 738 ± 168.5 543 ± 132.8 
2B17 197 ± 12.6 2680 ± 2.8 3960 ± 20.2 
Values shown are copy number × 104 normalized with GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase), mean ± S.D. 
 
  
Table 5.2 The expression of UGT in rat tissues at the detection levels167,169 
          UGT 
Tissue 
UGT1 UGT2 
Rat 1A1, 1A2, 1A3, 1A5, 1A6, 1A7, 
1A8 
2A1, 2B1, 2B2, 2B3, 2B6, 
2B8, 2B12 
Rat liver 1A1, 1A5, 1A6, 1A8 2B1, 2B2, 2B3, 2B6, 2B12 
Rat small intestine 1A1, 1A2, 1A3, 1A6, 1A7 2B3, 2B8, 2B12 
Rat colon 1A1, 1A2, 1A3, 1A6, 1A7 2B12 
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5.4. Interspecies Differences on EL Glucuronidation 
Interspecies differences in EL glucuronidation were also observed in my study. Rat is 
frequently used as an experimental model to evaluate the pharmacokinetic properties of 
xenobiotics including lignans, the data of which is significant to explore species differences to 
reduce the uncertainties related to data extrapolation from animals to humans. In my study, 
quantitative determination of EL glucuronidation was performed to determine the suitability 
of rat as a model to evaluate EL metabolism in humans. My evaluations suggested that some 
species discrepancies existed, especially with regard to intestinal metabolism. Based on the 
data, CLint value of human liver was only slightly higher than the value from rat liver, while 
the human intestinal CLint was much greater than the value either from RJM or RCM. Though 
the commercial human intestinal microsomes were a mixture of duodenum and jejunum 
tissues, the relatively great differences in CLint values imply human intestinal glucuronidation 
of EL was higher than that of rat intestine. These data suggests the human intestine might have 
a greater influence on the first-pass metabolism of EL, thereby decreasing EL’s oral 
bioavailability. Therefore, rat can be used as a reasonable model to evaluate the hepatic 
glucuronidation of EL occurring in humans, while the extent of intestinal glucuronidation of 
EL in humans might be underestimated when experiments are carried out on rats. 
 
5.5. The Significance of Km Value 
Km is defined as the substrate concentration that yields half the theoretical maximal 
velocity at infinite substrate concentration. The pharmacokinetic parameters Km, Vmax and 
CLint, play an important role in drug discovery and development, which aids to understand the 
importance of xenobiotic metabolizing enzymes in the clearance of new drug entity, thereby 
enabling the assessment of potential drug-drug interactions, the influence of genetic 
polymorphisms, and also possible non-linear dose-exposure172. Non-linear dose exposure is 
not solely dependent on but is significantly related to Km173. Km reflects the potential of a 
drug’s ability to saturate, or partially saturate, a specific enzyme in metabolism. The lower the 
Km value, the greater the affinity of the substrate to the enzyme, which might cause saturation 
of a metabolic clearance pathway at low drug concentrations depending upon enzyme capacity 
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(i.e. Vmax)173. This can be problematic with non-linear dose-exposure relationships, particular 
for drugs with low-therapeutic indices. Examples include cyclophosphamide, 5-fluorouracil, 
fluvoxamine, indinavir, and nefazodone, where a small increase in dose might cause toxicity 
as drug concentration in vivo will increase to a greater extent than expected154. The Km values 
for HLM and HIM are 8.91 and 12.6 µM, respectively, which are at least 2-fold smaller when 
compared with the values from RLM or rat intestinal microsomes (Table 4.3), implying EL 
has a higher affinity towards UGT enzymes in human liver and intestine than in rat tissues. 
Alternatively, this could reflect simple experimental variation. The higher affinity of EL 
towards UGT might result in drug-drug interactions with glucuronide drugs such as morphine. 
More than one UGT enzyme such as UGT2B7, 1A1, and 1A8 are suggested to metabolize 
morphine into the more potent and active metabolite morphine-6-glucuronide and inactive 
morphine-3-glucuronide, with a Km value over 60 µM174-176. Thus, the higher affinity of EL 
towards UGT might cause saturation of UGT enzymes or competitive inhibition, resulting in 
the decreased analgesic effects of morphine. Consequently, lignans or the initial dose of 
lignans should be regarded cautiously when coadministered with glucuronide drugs where the 
principal metabolic pathway involves UGT enzymes. Given only a two-fold difference in Km 
values, the rat might be a suitable model to estimate the interactions between EL and a 
coadministered compound.    
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6. CONCLUSIONS AND FUTURE WORK 
The purpose for this study is to provide an estimate of the relative contribution of the 
intestine and liver to presystemic glucuronidation of enterolactone (EL), thereby 
understanding the critical information regarding the oral absorption properties of EL. To fulfill 
this goal, in vitro enzyme kinetic studies using intestinal and liver microsomes from human 
and rat with determination of intrinsic clearance (CLint) using the substrate depletion approach 
was conducted to allow the comparison of differences of EL glucuronidation between the two 
first-pass metabolism organs and among these two species. Prior to carrying out the enzyme 
kinetic studies, it was necessary to make sure EL glucuronidation was able to occur in both 
human and rat intestinal and liver microsomes. In addition, an analytical method required 
validation to quantify EL in microsomes. Therefore, three objectives were established for my 
project. 
For my first objective, EL glucuronide (EL-Glu) was enzymatically generated by 
incubating EL with intestinal and liver microsomes from both human and rat. The formation 
and molecular identity of EL-Glu were substantiated by liquid chromatography-mass 
spectrometry (LC-MS). MS analysis suggested that two monoglucuronides were formed for 
EL incubated with rat liver microsomes (RLM), while only a single monoglucuronide was 
found for rat intestinal, human liver and intestinal microsomes.  
For my second objective, a simple and reliable HPLC method, which was developed in 
our lab, was employed for the quantitative determination of EL in RLM. The specificity was 
determined in the matrices including rat and human intestinal and liver microsomes. The 
results showed no interfering endogenous substances existed. The intra- and interday precision 
and accuracy for EL were ≤ 10%, suggesting this HPLC method was precise and accurate to 
quantify EL in rat and human liver and intestinal microsomes. 
For my final objective and the aim for my project, the in vitro CLint values of EL 
glucuronidation were examined using RLM, rat jejunum microsomes (RJM) and rat colon 
microsomes (RCM) extracted by myself in the lab and commercial sources of human liver 
microsomes (HLM) and human intestinal microsomes (HIM) by the substrate depletion 
approach. Overall, EL hepatic glucuronidation was greater than intestinal glucuronidation in 
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both human and rat, indicating liver is the predominant organ responsible for EL 
glucuronidation as expected. The in vitro CLint value of HLM was slightly higher than that of 
RLM. CLint value of human intestine was one third of human liver, suggesting the human 
intestine is likely to make a great contribution to the first-pass glucuronidation of EL, which 
might largely reduce the oral bioavailability of EL. The hepatic CLint value of rat was twenty 
times higher than that of the RJM or RCM, respectively. RJM and RCM gave comparable 
CLint values but were much lower than that of HIM. In brief, these results indicate rat can be 
used as models to evaluate hepatic glucuronidation of EL in humans, while experiments on 
rats may underestimate the extent of intestinal glucuronidation of EL that occurs in humans.  
In future, the UGT isoforms and their abundance responsible for EL glucuronidation in 
human liver and intestine need to be identified. This will provide insight into the importance 
of specific UGT enzymes to the pharmacokinetic properties of EL. Furthermore, the 
identification of specific UGT isoforms responsible for EL glucuronidation will potentially 
help avoid drug-drug interactions when lignans are coadministrated with drugs or other 
Natural Health Products (NPHs) that are predominantly metabolized by the same types of 
UGT. Pharmacokinetic information of EL-Glu needs to be investigated, as EL-Glu is the 
principal forms in human plasma. The determination of biological properties of EL-Glu will 
assist us to understand the lignan forms mediating the health beneficial effects. Additional 
pharmacokinetic information of EL needs to be thoroughly examined so that lignans can be 
consumed safely and efficiently.  	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APPENDIX I 
Table A.1 The natural log percent remaining for EL at multiple time points when a low EL 
concentration was incubated with rat liver microsomes 
Rat liver microsomes 
25 µM  The value of peak area 
ratios at multiple time 
points was normalized to 
t=0 
Percent  Ln percent 
Peak area ratios of analyte/IS 
at time t=0 min 
1.32 1 100 4.60 
Peak area ratios of analyte/IS 
at time t=2.5 min 
0.72 0.541 54.1 3.99 
Peak area ratios of analyte/IS 
at time t=5 min 
0.47 0.355 35.5 3.57 
Peak area ratios of analyte/IS 
at time t=7.5 min 
0.28 0.209 20.9 3.04 
Peak area ratios of analyte/IS 
at time t=10 min 
0.14 0.109 10.9 2.39 
Peak area ratios of analyte/IS 
at time t=12.5 min 
0.07 0.054 5.4 1.69 
Peak area ratios of analyte/IS 
at time t=15 min 
0.03 0.025 2.5 0.92 
A low EL concentration (25 µM) was chosen as an example to show the process of generating 
ln percent remaining, then to further plot a linear line to obtain kdep value for each EL 
concentration. 
 
 
Figure A.1 A plot of natural log percent remaining versus time 
 87 
Table A.2 The natural log percent remaining for EL at multiple time points when a high EL 
concentration was incubated with rat liver microsomes 
Rat liver microsomes 
300 µM  The value of peak area 
ratios at multiple time 
points is normalized to 
t=0 
Percent  Ln percent 
Peak area ratios of analyte/IS 
at time t=0 min 
14.97 1 100 4.60 
Peak area ratios of analyte/IS 
at time t=5 min 
11.80 0.788 78.8 4.37 
Peak area ratios of analyte/IS 
at time t=10 min 
10.70 0.715 71.5 4.27 
Peak area ratios of analyte/IS 
at time t=15 min 
9.62 0.643 64.3 4.16 
Peak area ratios of analyte/IS 
at time t=20 min 
8.49 0.567 56.7 4.04 
Peak area ratios of analyte/IS 
at time t=25 min 
7.21 0.482 48.2 3.88 
Peak area ratios of analyte/IS 
at time t=30 min 
5.77 0.385 38.5 3.65 
A high EL concentration (300 µM) was chosen as an example to show the process of 
generating ln percent remaining, then to further plot a linear line to obtain kdep value for each 
EL concentration. 
 
	  
 
Figure A.2 A plot of natural log percent remaining versus time 
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Table A.3 Various EL concentrations (10 - 500µM) versus percent remaining for rat liver 
microsomal kinetic study 
EL Concentration (µM) Final percent remaining  kdep (min-1) 
10 2.6 0.362 
25 2.5 0.241 
50 1.7 0.198 
75 5.5 0.141 
100 5.4 0.0916 
200 35.6 0.0335 
300 38.5 0.0291 
500 70.8 0.0110 
 
 
Table A.4 Various EL concentrations (1.5 - 100µM) versus percent remaining for rat jejunum 
microsomal kinetic study 
EL Concentration (µM) Final percent remaining  kdep (min-1) 
1.5 42.6 0.0273 
3 58.2 0.0208 
6 55.3 0.0195 
10 57.7 0.0177 
20 60.1 0.0159 
30 64.5 0.0139 
50 78.1 0.0086 
100 78.3 0.0077 
 
 
Table A.5 Various EL concentrations (1.5 - 100µM) versus percent remaining for rat colon 
microsomal kinetic study 
EL Concentration (µM) Final percent remaining  kdep (min-1) 
1.5 45.8 0.0309 
4.5 45 0.0248 
6 44.7 0.0239 
10 48.4 0.0229 
20 52.5 0.0201 
50 58 0.0164 
100 77.9 0.0077 
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Table A.6 Various EL concentrations (10 - 500µM) versus percent remaining for human liver 
microsomal kinetic study 
EL Concentration (µM) Final percent remaining  kdep (min-1) 
10 1.5 0.276 
25 1.3 0.165 
37.5 2.3 0.117 
50 5 0.0917 
75 16.2 0.0556 
100 27.5 0.0402 
150 42.3 0.0277 
200 45.3 0.0238 
300 66.5 0.0127 
500 80.7 0.0070 
 
 
 
Table A.7 Various EL concentrations (10 - 300µM) versus percent remaining for human 
intestinal microsomal kinetic study 
EL Concentration (µM) Final percent remaining  kdep (min-1) 
10 6.4 0.0871 
17.5 14.6 0.0601 
25 17.4 0.0557 
37.5 25.4 0.0414 
50 35.9 0.0317 
75 50.5 0.0223 
100 63.8 0.0138 
150 68.6 0.0119 
200 79 0.0077 
300 84.9 0.0051 
 
